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Introduction: Adenocarcinoma is the most common histologic type
of lung cancer. To address advances in oncology, molecular biology,
pathology, radiology, and surgery of lung adenocarcinoma, an in-
ternational multidisciplinary classification was sponsored by the
International Association for the Study of Lung Cancer, American
Thoracic Society, and European Respiratory Society. This new
adenocarcinoma classification is needed to provide uniform termi-
nology and diagnostic criteria, especially for bronchioloalveolar
carcinoma (BAC), the overall approach to small nonresection cancer
specimens, and for multidisciplinary strategic management of tissue
for molecular and immunohistochemical studies.
Methods: An international core panel of experts representing all
three societies was formed with oncologists/pulmonologists, pathol-
ogists, radiologists, molecular biologists, and thoracic surgeons. A
systematic review was performed under the guidance of the American
Thoracic Society Documents Development and Implementation Commit-
tee. The search strategy identified 11,368 citations ofwhich 312 articlesmet
specified eligibility criteria and were retrieved for full text review. A series
of meetings were held to discuss the development of the new classification,
to develop the recommendations, and to write the current document.
Recommendations for key questionswere graded by strength and quality of
the evidence according to the Grades of Recommendation, Assessment,
Development, and Evaluation approach.
Results: The classification addresses both resection specimens, and
small biopsies and cytology. The terms BAC and mixed subtype
adenocarcinoma are no longer used. For resection specimens, new
concepts are introduced such as adenocarcinoma in situ (AIS) and
minimally invasive adenocarcinoma (MIA) for small solitary adenocar-
cinomas with either pure lepidic growth (AIS) or predominant lepidic
growth with 5 mm invasion (MIA) to define patients who, if they
undergo complete resection, will have 100% or near 100% disease-
specific survival, respectively. AIS and MIA are usually nonmucinous
but rarely may be mucinous. Invasive adenocarcinomas are classified
by predominant pattern after using comprehensive histologic subtyping
with lepidic (formerly most mixed subtype tumors with nonmucinous
BAC), acinar, papillary, and solid patterns; micropapillary is added as
a new histologic subtype. Variants include invasive mucinous adeno-
carcinoma (formerly mucinous BAC), colloid, fetal, and enteric adeno-
carcinoma. This classification provides guidance for small biopsies and
cytology specimens, as approximately 70% of lung cancers are diag-
nosed in such samples. Non-small cell lung carcinomas (NSCLCs), in
patients with advanced-stage disease, are to be classified into more
specific types such as adenocarcinoma or squamous cell carcinoma,
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whenever possible for several reasons: (1) adenocarcinoma or NSCLC
not otherwise specified should be tested for epidermal growth factor
receptor (EGFR) mutations as the presence of these mutations is
predictive of responsiveness to EGFR tyrosine kinase inhibitors, (2)
adenocarcinoma histology is a strong predictor for improved outcome
with pemetrexed therapy compared with squamous cell carcinoma, and
(3) potential life-threatening hemorrhage may occur in patients with
squamous cell carcinoma who receive bevacizumab. If the tumor
cannot be classified based on light microscopy alone, special studies
such as immunohistochemistry and/or mucin stains should be applied to
classify the tumor further. Use of the term NSCLC not otherwise
specified should be minimized.
Conclusions: This new classification strategy is based on a multidis-
ciplinary approach to diagnosis of lung adenocarcinoma that incorpo-
rates clinical, molecular, radiologic, and surgical issues, but it is pri-
marily based on histology. This classification is intended to support
clinical practice, and research investigation and clinical trials. As EGFR
mutation is a validated predictive marker for response and progression-
free survival with EGFR tyrosine kinase inhibitors in advanced lung
adenocarcinoma, we recommend that patients with advanced adenocar-
cinomas be tested for EGFR mutation. This has implications for
strategicmanagement of tissue, particularly for small biopsies and cytology
samples, to maximize high-quality tissue available for molecular studies.
Potential impact for tumor, node, andmetastasis staging include adjustment
of the size T factor according to only the invasive component (1) patho-
logically in invasive tumors with lepidic areas or (2) radiologically by
measuring the solid component of part-solid nodules.
Key Words: Lung, Adenocarcinoma, Classification, Histologic,
Pathology, Oncology, Pulmonary, Radiology, Computed tomogra-
phy, Molecular, EGFR, KRAS, EML4-ALK, Gene profiling, Gene
amplification, Surgery, Limited resection, Bronchioloalveolar carci-
noma, Lepidic, Acinar, Papillary, Micropapillary, Solid, Adenocar-
cinoma in situ, Minimally invasive adenocarcinoma, Colloid, Mu-
cinous cystadenocarcinoma, Enteric, Fetal, Signet ring, Clear cell,
Frozen section, TTF-1, p63.
(J Thorac Oncol. 2011;6: 244–285)
RATIONALE FOR A CHANGE IN THE
APPROACH TO CLASSIFICATION OF LUNG
ADENOCARCINOMA
Lung cancer is the most frequent cause of major cancer
incidence and mortality worldwide.1,2 Adenocarcinoma is the
most common histologic subtype of lung cancer in most coun-
tries, accounting for almost half of all lung cancers.3 A widely
divergent clinical, radiologic, molecular, and pathologic spec-
trum exists within lung adenocarcinoma. As a result, confusion
exists, and studies are difficult to compare. Despite remarkable
advances in understanding of this tumor in the past decade, there
remains a need for universally accepted criteria for adenocarci-
noma subtypes, in particular tumors formerly classified as bron-
chioloalveolar carcinoma (BAC).4,5 As enormous resources are
being spent on trials involving molecular and therapeutic aspects
of adenocarcinoma of the lung, the development of standardized
criteria is of great importance and should help advance the field,
increasing the impact of research, and improving patient care.
This classification is needed to assist in determining patient
therapy and predicting outcome.
NEED FOR A MULTIDISCIPLINARY APPROACH
TO DIAGNOSIS OF LUNG ADENOCARCINOMA
One of the major outcomes of this project is the
recognition that the diagnosis of lung adenocarcinoma re-
quires a multidisciplinary approach. The classifications of
lung cancer published by the World Health Organization
(WHO) in 1967, 1981, and 1999 were written primarily by
pathologists for pathologists.5–7 Only in the 2004 revision,
relevant genetics and clinical information were introduced.4
Nevertheless, because of remarkable advances over the last 6
years in our understanding of lung adenocarcinoma, particu-
larly in area of medical oncology, molecular biology, and
radiology, there is a pressing need for a revised classification,
based not on pathology alone, but rather on an integrated
multidisciplinary platform. In particular, there are two major
areas of interaction between specialties that are driving the
need for our multidisciplinary approach to classification of
lung adenocarcinoma: (1) in patients with advanced non-
small cell lung cancer, recent progress in molecular biology
and oncology has led to (a) discovery of epidermal growth
factor receptor (EGFR) mutation and its prediction of re-
sponse to EGFR tyrosine kinase inhibitors (TKIs) in adeno-
carcinoma patients8–11 and (b) the requirement to exclude a
diagnosis of squamous cell carcinoma to determine eligibility
patients for treatment with pemetrexed, (because of improved
efficacy)12–15 or bevacizumab (because of toxicity)16,17 and
(2) the emergence of radiologic-pathologic correlations be-
tween ground-glass versus solid or mixed opacities seen by
computed tomography (CT) and BAC versus invasive growth
by pathology have opened new opportunities for imaging
studies to be used by radiologists, pulmonologists, and sur-
geons for predicting the histologic subtype of adenocarcino-
mas,18–21 patient prognosis,18–23 and improve preoperative
assessment for choice of timing and type of surgical inter-
vention.18–26
Although histologic criteria remain the foundation of
this new classification, this document has been developed by
pathologists in collaboration with clinical, radiology, molec-
ular, and surgical colleagues. This effort has led to the
development of terminology and criteria that not only define
pathologic entities but also communicate critical information
that is relevant to patient management (Tables 1 and 2). The
classification also provides recommendations on strategic
handling of specimens to optimize the amount of information
to be gleaned. The goal is not only longer to solely provide
the most accurate diagnosis but also to manage the tissue in
a way that immunohistochemical and/or molecular studies
can be performed to obtain predictive and prognostic data that
will lead to improvement in patient outcomes.
For the first time, this classification addresses an ap-
proach to small biopsies and cytology in lung cancer diag-
nosis (Table 2). Recent data regarding EGFR mutation pre-
dicting responsiveness to EGFR-TKIs,8–11 toxicities,16 and
therapeutic efficacy12–15 have established the importance of
distinguishing squamous cell carcinoma from adenocarci-
noma and non-small cell lung carcinoma (NSCLC) not oth-
erwise specified (NOS) in patients with advanced lung can-
cer. Approximately 70% of lung cancers are diagnosed and
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staged by small biopsies or cytology rather than surgical
resection specimens, with increasing use of transbronchial
needle aspiration (TBNA), endobronchial ultrasound-guided
TBNA and esophageal ultrasound-guided needle aspiration.27
Within the NSCLC group, most pathologists can identify
well- or moderately differentiated squamous cell carcinomas
or adenocarcinomas, but specific diagnoses are more difficult
with poorly differentiated tumors. Nevertheless, in small
biopsies and/or cytology specimens, 10 to 30% of specimens
continue to be diagnosed as NSCLC-NOS.13,28,29
Proposed terminology to be used in small biopsies is
summarized in Table 2. Pathologists need to minimize the use
of the term NSCLC or NSCLC-NOS on small samples and
aspiration and exfoliative cytology, providing as specific a
histologic classification as possible to facilitate the treatment
approach of medical oncologists.30
Unlike previous WHO classifications where the pri-
mary diagnostic criteria for as many tumor types as possible
were based on hematoxylin and eosin (H&E) examination,
this classification emphasizes the use and integration of
immunohistochemical (i.e., thyroid transcription factor [TTF-
1]/p63 staining), histochemical (i.e., mucin staining), and
molecular studies, as specific therapies are driven histologic
subtyping. Although these techniques should be used when-
ever possible, it is recognized that this may not always be
possible, and thus, a simpler approach is also provided when
only H&E-stained slides are available, so this classification
may be applicable even in a low resource setting.
METHODOLOGY
Objectives
This international multidisciplinary classification has been
produced as a collaborative effort by the International Associa-
tion for the Study of Lung Cancer (IASLC), the American
Thoracic Society (ATS), and the European Respiratory Society.
The purpose is to provide an integrated clinical, radiologic,
molecular, and pathologic approach to classification of the var-
ious types of lung adenocarcinoma that will help to define
categories that have distinct clinical, radiologic, molecular, and
pathologic characteristics. The goal is to identify prognostic and
predictive factors and therapeutic targets.
Participants
Panel members included thoracic medical oncologists,
pulmonologists, radiologists, molecular biologists, thoracic
surgeons, and pathologists. The supporting associations nom-
inated panel members. The cochairs were selected by the
IASLC. Panel members were selected because of special
interest and expertise in lung adenocarcinoma and to provide
an international and multidisciplinary representation. The
panel consisted of a core group (author list) and a reviewer
group (Appendix 1, see Supplemental Digital Content 1
available at http://links.lww.com/JTO/A59, affiliations for
coauthors are listed in appendix).
Evidence
The panel performed a systematic review with guidance
by members of the ATS Documents Development and Im-
plementation Committee. Key questions for this project were
generated by each specialty group, and a search strategy was
developed (Appendix 2, see Supplemental Digital Content
2 available at http://links.lww.com/JTO/A60). Searches were
performed in June 2008 with an update in June 2009 resulting
in 11,368 citations. These were reviewed to exclude articles
that did not have any relevance to the topic of lung adeno-
carcinoma classification. The remaining articles were evalu-
ated by two observers who rated them by a predetermined set
of eligibility criteria using an electronic web-based survey
program (www.surveymonkey.com) to collect responses.31 This
process narrowed the total number of articles to 312 that were
reviewed in detail for a total of 141 specific features, including
17 study characteristics, 35 clinical, 48 pathologic, 16 radio-
logic, 16 molecular, and nine surgical (Appendix 2). These 141
features were summarized in an electronic database that was
distributed to members of the core panel, including the writing
committee. Articles chosen for specific data summaries were
reviewed, and based on analysis of tables from this systematic
review, recommendations were made according to the Grades of
Recommendation, Assessment, Development, and Evaluation
(GRADE).32–37 Throughout the rest of the document, the term
GRADE (spelled in capital letters) must be distinguished from
histologic grade, which is a measure of pathologic tumor differ-
entiation. The GRADE system has two major components: (1)
grading the strength of the recommendation and (2) evaluating
the quality of the evidence.32 The strength of recommendations
is based on weighing estimates of benefits versus downsides.
Evidence was rated as high, moderate, or low or very low.32 The
TABLE 1. IASLC/ATS/ERS Classification of Lung
Adenocarcinoma in Resection Specimens
Preinvasive lesions
Atypical adenomatous hyperplasia
Adenocarcinoma in situ (3 cm formerly BAC)
Nonmucinous
Mucinous
Mixed mucinous/nonmucinous
Minimally invasive adenocarcinoma (3 cm lepidic predominant tumor
with 5 mm invasion)
Nonmucinous
Mucinous
Mixed mucinous/nonmucinous
Invasive adenocarcinoma
Lepidic predominant (formerly nonmucinous BAC pattern, with 5 mm
invasion)
Acinar predominant
Papillary predominant
Micropapillary predominant
Solid predominant with mucin production
Variants of invasive adenocarcinoma
Invasive mucinous adenocarcinoma (formerly mucinous BAC)
Colloid
Fetal (low and high grade)
Enteric
BAC, bronchioloalveolar carcinoma; IASLC, International Association for the
Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory
Society.
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quality of the evidence expresses the confidence in an estimate
of effect or an association and whether it is adequate to support
a recommendation. After review of all articles, a writing com-
mittee met to develop the recommendations with each specialty
group proposing the recommendations, votes for or against the
recommendation, and modifications were conducted after mul-
tidisciplinary discussion. If randomized trials were available, we
started by assuming high quality but down-graded the quality
when there were serious methodological limitations, indirectness
in population, inconsistency in results, imprecision in estimates,
or a strong suspicion of publication bias. If well-done observa-
tional studies were available, low-quality evidence was as-
sumed, but the quality was upgraded when there was a
large treatment effect or a large association, all plausible
residual confounders would diminish the effects, or if there was
a dose-response gradient.36 We developed considerations for
good practice related to interventions that usually represent
necessary and standard procedures of health care system—such
as history taking and physical examination helping patients to
make informed decisions, obtaining written consent, or the
importance of good communication—when we considered them
helpful. In that case, we did not perform a grading of the quality
of evidence or strength of the recommendations.38
Meetings
Between March 2008 and December 2009, a series of
meetings were held, mostly at Memorial Sloan Kettering
Cancer Center, in New York, NY, to discuss issues related to
TABLE 2. Proposed IASLC/ATS/ERS Classification for Small Biopsies/Cytology
IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; WHO, World Health Organization;
NSCLC, non-small cell lung cancer; IHC, immunohistochemistry; TTF, thyroid transcription factor.
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lung adenocarcinoma classification and to formulate this
document. The core group established a uniform and consis-
tent approach to the proposed types of lung adenocarcinoma.
Validation
Separate projects were initiated by individuals involved
with this classification effort in an attempt to develop data to
test the proposed system. These included projects on small
biopsies,39,40 histologic grading,41–43 stage I adenocarcino-
mas,44 small adenocarcinomas from Japan, international mul-
tiple pathologist project on reproducibility of recognizing
major histologic patterns of lung adenocarcinoma,45 molecu-
lar-histologic correlations, and radiologic-pathologic correla-
tion focused on adenocarcinoma in situ (AIS), and minimally
invasive adenocarcinoma (MIA).
The new proposals in this classification are based on the
best available evidence at the time of writing this document.
Nevertheless, because of the lack of universal diagnostic
criteria in the literature, there is a need for future validation
studies based on these standardized pathologic criteria with
clinical, molecular, radiologic, and surgical correlations.
PATHOLOGIC CLASSIFICATION
Histopathology is the backbone of this classification, but
lung cancer diagnosis is a multidisciplinary process requiring
correlation with clinical, radiologic, molecular, and surgical
information. Because of the multidisciplinary approach in de-
veloping this classification, we are recommending significant
changes that should improve the diagnosis and classification of
lung adenocarcinoma, resulting in therapeutic benefits.
Even after publication of the 1999 and 2004 WHO clas-
sifications,4,5 the former term BAC continues to be used for a
broad spectrum of tumors including (1) solitary small noninva-
sive peripheral lung tumors with a 100% 5-year survival,46 (2)
invasive adenocarcinomas with minimal invasion that have ap-
proximately 100% 5-year survival,47,48 (3) mixed subtype in-
vasive adenocarcinomas,49–53 (4) mucinous and nonmuci-
nous subtypes of tumors formerly known as BAC,50–52,54,55
and (5) widespread advanced disease with a very low
survival rate.4,5 The consequences of confusion from the
multiple uses of the former BAC term in the clinical and
research arenas have been the subject of many reviews and
editorials and are addressed throughout this document.55–61
Pathology Recommendation 1
We recommend discontinuing the use of the term
“BAC.” Strong recommendation, low-quality evidence.
Throughout this article, the term BAC (applicable to
multiple places in the new classification, Table 3), will be
referred to as “former BAC.” We understand this will be a
major adjustment and suggest initially that when the new
proposed terms are used, it will be accompanied in parenthe-
ses by “(formerly BAC).” This transition will impact not only
clinical practice and research but also cancer registries future
analyses of registry data.
CLASSIFICATION FOR RESECTION SPECIMENS
Multiple studies have shown that patients with small
solitary peripheral adenocarcinomas with pure lepidic growth
may have 100% 5-year disease-free survival.46,62–68 In addi-
tion, a growing number of articles suggest that patients with
lepidic predominant adenocarcinomas (LPAs) with minimal
invasion may also have excellent survival.47,48 Recent work
has demonstrated that more than 90% of lung adenocarcino-
mas fall into the mixed subtype according to the 2004 WHO
classification, so it has been proposed to use comprehensive
histologic subtyping to make a semiquantitative assessment
of the percentages of the various histologic components:
acinar, papillary, micropapillary, lepidic, and solid and to
classify tumors according to the predominant histologic sub-
type.69 This has demonstrated an improved ability to address
the complex histologic heterogeneity of lung adenocarcino-
mas and to improve molecular and prognostic correlations.69
The new proposed lung adenocarcinoma classification
for resected tumors is summarized in Table 1.
Preinvasive Lesions
In the 1999 and 2004 WHO classifications, atypical
adenomatous hyperplasia (AAH) was recognized as a prein-
vasive lesion for lung adenocarcinoma. This is based on
multiple studies documenting these lesions as incidental find-
ings in the adjacent lung parenchyma in 5 to 23% of resected
lung adenocarcinomas70–74 and a variety of molecular find-
ings that demonstrate a relationship to lung adenocarcinoma
including clonality,75,76 KRAS mutation,77,78 KRAS polymor-
phism,79 EGFR mutation,80 p53 expression,81 loss of het-
erozygosity,82 methylation,83 telomerase overexpression,84
eukaryotic initiation factor 4E expression,85 epigenetic alter-
ations in the Wnt pathway,86 and FHIT expression.87 Depend-
ing on the extensiveness of the search, AAH may be multiple
in up to 7% of resected lung adenocarcinomas.71,88
A major change in this classification is the official
recognition of AIS, as a second preinvasive lesion for lung
adenocarcinoma in addition to AAH. In the category of
preinvasive lesions, AAH is the counterpart to squamous
dysplasia and AIS the counterpart to squamous cell carci-
noma in situ.
Atypical Adenomatous Hyperplasia
AAH is a localized, small (usually 0.5 cm or less)
proliferation of mildly to moderately atypical type II pneu-
mocytes and/or Clara cells lining alveolar walls and some-
times, respiratory bronchioles (Figures 1A, B).4,89,90 Gaps are
TABLE 3. Categories of New Adenocarcinoma Classification
Where Former BAC Concept was Used
1. Adenocarcinoma in situ (AIS), which can be nonmucinous and rarely
mucinous
2. Minimally invasive adenocarcinoma (MIA), which can be nonmucinous
and rarely mucinous
3. Lepidic predominant adenocarcinoma (nonmucinous)
4. Adenocarcinoma, predominantly invasive with some nonmucinous
lepidic component (includes some resected tumors, formerly classified
as mixed subtype, and some clinically advanced adenocarcinomas
formerly classified as nonmucinous BAC)
5. Invasive mucinous adenocarcinoma (formerly mucinous BAC)
BAC, bronchioloalveolar carcinoma.
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usually seen between the cells, which consist of rounded,
cuboidal, low columnar, or “peg” cells with round to oval
nuclei (Figure 1B). Intranuclear inclusions are frequent.
There is a continuum of morphologic changes between AAH
and AIS.4,89,90 A spectrum of cellularity and atypia occurs in
AAH. Although some have classified AAH into low- and
high-grade types,84,91 grading is not recommended.4 Distinc-
tion between more cellular and atypical AAH and AIS can be
difficult histologically and impossible cytologically.
AIS, Nonmucinous, and/or Mucinous
AIS (one of the lesions formerly known as BAC) is a
localized small (3 cm) adenocarcinoma with growth re-
stricted to neoplastic cells along preexisting alveolar struc-
tures (lepidic growth), lacking stromal, vascular, or pleural
invasion. Papillary or micropapillary patterns and intraalveo-
lar tumor cells are absent. AIS is subdivided into nonmuci-
nous and mucinous variants. Virtually, all cases of AIS are
nonmucinous, consisting of type II pneumocytes and/or Clara
cells (Figures 2A, B). There is no recognized clinical signif-
icance to the distinction between type II or Clara cells, so this
morphologic separation is not recommended. The rare cases
of mucinous AIS consist of tall columnar cells with basal
nuclei and abundant cytoplasmic mucin; sometimes they
resemble goblet cells (Figures 3A, B). Nuclear atypia is
absent or inconspicuous in both nonmucinous and mucinous
AIS (Figures 2B and 3B). Septal widening with sclerosis is
common in AIS, particularly the nonmucinous variant.
Tumors that meet criteria for AIS have formerly been
classified as BAC according to the strict definition of the
1999 and 2004 WHO classifications and type A and type B
adenocarcinoma according to the 1995 Noguchi classifica-
tion.4,46 Multiple observational studies on solitary lung ade-
nocarcinomas with pure lepidic growth, smaller than either 2
or 3 cm have documented 100% disease-free survival.46,62–68
Although most of these tumors are nonmucinous, 2 of the 28
tumors reported by Noguchi as types A and B in the 1995
study were mucinous.46 Small size (3 cm) and a discrete
circumscribed border are important to exclude cases with
miliary spread into adjacent lung parenchyma and/or lobar
consolidation, particularly for mucinous AIS.
Pathology Recommendation 2
For small (3 cm), solitary adenocarcinomas with pure
lepidic growth, we recommend the term “Adenocarcinoma in
situ” that defines patients who should have 100% disease-
specific survival, if the lesion is completely resected (strong
recommendation, moderate quality evidence).
Remark: Most AIS are nonmucinous, rarely are they
mucinous.
MIA, Nonmucinous, and/or Mucinous
MIA is a small, solitary adenocarcinoma (3 cm), with
a predominantly lepidic pattern and 5 mm invasion in
greatest dimension in any one focus.47,48,92 MIA is usually
nonmucinous (Figures 4A–C) but rarely may be mucinous
(Figures 5A, B).44 MIA is, by definition, solitary and discrete.
The criteria for MIA can be applied in the setting of multiple
tumors only if the other tumors are regarded as synchronous
primaries rather than intrapulmonary metastases.
The invasive component to be measured in MIA is de-
fined as follows: (1) histological subtypes other than a lepidic
pattern (i.e., acinar, papillary, micropapillary, and/or solid) or (2)
tumor cells infiltrating myofibroblastic stroma. MIA is excluded
if the tumor (1) invades lymphatics, blood vessels, or pleura or
(2) contains tumor necrosis. If multiple microinvasive areas are
found in one tumor, the size of the largest invasive area should
be measured in the largest dimension, and it should be 5 mm
FIGURE 1. Atypical adenomatous hyperplasia. A, This
3-mm nodular lesion consists of atypical pneumocytes prolif-
erating along preexisting alveolar walls. There is no invasive
component. B, The slightly atypical pneumocytes are cuboi-
dal and show gaps between the cells. Nuclei are hyperchro-
matic, and a few show nuclear enlargement and multinucle-
ation.
FIGURE 2. Nonmucinous adenocarcinoma in situ. A, This
circumscribed nonmucinous tumor grows purely with a lepi-
dic pattern. No foci of invasion or scarring are seen. B, The
tumor shows atypical pneumocytes proliferating along the
slightly thickened, but preserved, alveolar walls.
FIGURE 3. Mucinous adenocarcinoma in situ. A, This muci-
nous AIS consists of a nodular proliferation of mucinous co-
lumnar cells growing in a purely lepidic pattern. Although
there is a small central scar, no stromal or vascular invasion
is seen. B, The tumor cells consist of cuboidal to columnar
cells with abundant apical mucin and small basally oriented
nuclei. AIS, adenocarcinoma in situ.
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in size. The size of invasion is not the summation of all such
foci, if more than one occurs. If the manner of histologic
sectioning of the tumor makes it impossible to measure the size
of invasion, an estimate of invasive size can be made by
multiplying the total percentage of the invasive (nonlepidic)
components times the total tumor size.
Evidence for a category of MIA with 100% disease-free
survival can be found in the 1995 article by Noguchi et al.,
where vascular or pleural invasion was found in 10% of the
small solitary lung adenocarcinomas that otherwise met the
former definition of pure BAC. Even these focally invasive
tumors also showed 100% disease-free survival.46 Subsequent
articles by Suzuki et al. and Sakurai et al.19,21 defined subsets of
small lung adenocarcinomas with 100% disease-free survival
using scar size less than 5 mm and stromal invasion in the area
of bronchioloalveolar growth, respectively. More recently, arti-
cles by Yim et al., Borczuk et al., and Maeshima et al.47,48,92
have described patients with MIA defined similar to the above
criteria, and these have demonstrated near 100% disease specific
or very favorable overall survival. There is very limited data
regarding mucinous MIA; however, this seems to exist. A
mucinous MIA with a minor mixture of a nonmucinous com-
ponent is being reported.44 The recent report by Sawada et al.93
of localized mucinous BAC may have included a few cases of
mucinous AIS or MIA, but details of the pathology are not
specific enough to be certain. A recent series of surgically
resected solitary mucinous BAC did not document histologically
whether focal invasion was present or not, so AIS versus MIA
status cannot be determined, but all eight patients with tumors
measuring 3 cm had 100% overall 5-year survival rates.94
Presentation as a solitary mass, small size, and a discrete cir-
cumscribed border is important to exclude cases of miliary
involvement of adjacent lung parenchyma and/or lobar consol-
idation, particularly for mucinous AIS.
Pathology Recommendation 3
For small (3 cm), solitary, adenocarcinomas with pre-
dominant lepidic growth and small foci of invasion measuring
0.5 cm, we recommend a new concept of “Minimally invasive
adenocarcinoma” to define patients who have near 100%, dis-
ease-specific survival, if completely resected (strong recommen-
dation, low-quality evidence).
Remark: Most MIA are nonmucinous, rarely are they
mucinous.
Tumor Size and Specimen Processing Issues for
AIS and MIA
The diagnosis of AIS or MIA cannot be firmly established
without entire histologic sampling of the tumor. If tumor pro-
curement is performed, it should be done strategically as dis-
cussed in the molecular section.
Because most of the literature on the topic of AIS and
MIA deal with tumors 2.0 or 3.0 cm or less, there is insufficient
evidence to support that 100% disease-free survival can occur in
completely resected, solitary tumors suspected to be AIS orMIA
that are larger than 3.0 cm. Until data validate 100% disease-free
survival for completely resected, solitary, adenocarcinomas
larger than 3.0 cm suspected to be AIS or MIA after complete
sampling, the term “lepidic predominant adenocarcinoma, sus-
pect AIS or MIA” is suggested. In such a tumor larger than 3.0
cm, particularly if it has not been completely sampled, the term
“lepidic predominant adenocarcinoma” is best applied with a
comment that the clinical behavior is uncertain and/or that an
invasive component cannot be excluded.
Invasive Adenocarcinoma
As invasive adenocarcinomas represent more than 70 to
90% of surgically resected lung cases, one of the most important
aspects of this classification is to present a practical way to
address these tumors that are composed of a complex heteroge-
neous mixture of histologic subtypes. This complex mixture of
histologic subtypes has presented one of the greatest challenges
to classification of invasive lung adenocarcinomas. In recent
years, multiple independent research groups have begun to
classify lung adenocarcinomas according to the most predomi-
nant subtype.43,44,69,95–102 This approach provides better stratifi-
FIGURE 4. Nonmucinous minimally invasive adenocarci-
noma. A, This subpleural adenocarcinoma tumor consists
primarily of lepidic growth with a small (0.5 cm) central
area of invasion. B, To the left is the lepidic pattern and on
the right is an area of acinar invasion. C, These acinar glands
are invading in the fibrous stroma.
FIGURE 5. Mucinous minimally invasive adenocarcinoma.
A, This mucinous MIA consists of a tumor showing lepidic
growth and a small (0.5 cm) area of invasion. B, The tu-
mor cells consist of mucinous columnar cells growing mostly
in a lepidic pattern along the surface of alveolar walls. The
tumor invades the areas of stromal fibrosis in an acinar pat-
tern. MIA, minimally invasive adenocarcinoma.
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cation of the “mixed subtype” lung adenocarcinomas according
to the 1999/2004 WHO Classifications and has allowed for
novel correlations between histologic subtypes and both molec-
ular and clinical features.43,44,69,95–102
In the revised classification, the term “predominant” is
appended to all categories of invasive adenocarcinoma, as most
of these tumors consist of mixtures of the histologic subtypes
(Figures 6A–C). This replaces the use of the term adenocarci-
noma, mixed subtype. Semiquantitative recording of the patterns
in 5% increments encourages the observer to identify all patterns
that may be present, rather than focusing on a single pattern (i.e.,
lepidic growth). This method provides a basis for choosing the
predominant pattern. Although most previous studies on this
topic used 10% increments, using 5% allows for greater flexi-
bility in choosing a predominant subtype when tumors have two
patterns with relatively similar percentages; it also avoids the
need to use 10% for small amounts of components that may be
prognostically important such as micropapillary or solid pat-
terns. Recording of these percentages also makes it clear to the
reader of a report when a tumor has relatively even mixtures of
several patterns versus a single dominant pattern. In addition, it
provides a way to compare the histology of multiple adenocar-
cinomas (see later).102 This approach may also provide a basis
for architectural grading of lung adenocarcinomas.43 A recent
reproducibility study of classical and difficult selected images of
the major lung adenocarcinoma subtypes circulated among a
panel of 26 expert lung cancer pathologists documented kappa
values of 0.77  0.07 and 0.38  0.14, respectively.45 This
study did not test recognition of predominant subtype.
Pathology Recommendation 4
For invasive adenocarcinomas, we suggest comprehen-
sive histologic subtyping be used to assess histologic patterns
semiquantitatively in 5% increments, choosing a single predom-
inant pattern. Individual tumors are then classified according to
the predominant pattern and the percentages of the subtypes are
also reported (weak recommendation, low-quality evidence).
Histologic Comparison of Multiple
Adenocarcinomas and Impact on Staging
Comprehensive histologic subtyping can be useful in
comparing multiple lung adenocarcinomas to distinguish multi-
ple primary tumors from intrapulmonary metastases. This has a
great impact on staging for patients with multiple lung adeno-
carcinomas. Recording the percentages of the various histologic
types in 5% increments, not just the most predominant type,
allows these data to be used to compare multiple adenocarcino-
mas, particularly if the slides of a previous tumor are not
available at the time of review of the additional lung tumors.102
In addition to comprehensive histologic subtyping, other histo-
logic features of the tumors such as cytologic (clear cell or signet
ring features) or stromal (desmoplasia or inflammation) charac-
teristics may be helpful to compare multiple tumors.102
Pathology Recommendation 5
In patients with multiple lung adenocarcinomas, we sug-
gest comprehensive histologic subtyping may facilitate in the
comparison of the complex, heterogeneous mixtures of histo-
logic patterns to determine whether the tumors are metastases or
separate synchronous or metachronous primaries (weak recom-
mendation, low-quality evidence).
FIGURE 6. Major histologic patterns of invasive adenocarci-
noma. A, Lepidic predominant pattern with mostly lepidic
growth (right) and a smaller area of invasive acinar adeno-
carcinoma (left). B, Lepidic pattern consists of a proliferation
type II pneumocytes and Clara cells along the surface alveo-
lar walls. C, Area of invasive acinar adenocarcinoma (same
tumor as in A and B). D, Acinar adenocarcinoma consists of
round to oval-shaped malignant glands invading a fibrous
stroma. E, Papillary adenocarcinoma consists of malignant
cuboidal to columnar tumor cells growing on the surface of
fibrovascular cores. F, Micropapillary adenocarcinoma con-
sists of small papillary clusters of glandular cells growing
within this airspace, most of which do not show fibrovascu-
lar cores. G, Solid adenocarcinoma with mucin consisting of
sheets of tumor cells with abundant cytoplasm and mostly
vesicular nuclei with several conspicuous nucleoli. No acinar,
papillary, or lepidic patterns are seen, but multiple cells have
intracytoplasmic basophilic globules that suggest intracyto-
plasmic mucin. H, Solid adenocarcinoma with mucin. Nu-
merous intracytoplasmic droplets of mucin are highlighted
with this DPAS stain. DPAS, diastase-periodic acid Schiff.
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LPA typically consists of bland pneumocytic cells (type II
pneumocytes or Clara cells) growing along the surface of alve-
olar walls similar to the morphology defined in the above section
on AIS and MIA (Figures 6A, B). Invasive adenocarcinoma is
present in at least one focus measuring more than 5 mm in
greatest dimension. Invasion is defined as (1) histological sub-
types other than a lepidic pattern (i.e., acinar, papillary, micro-
papillary, and/or solid) or (2) myofibroblastic stroma associated
with invasive tumor cells (Figure 6C). The diagnosis of LPA
rather than MIA is made if the tumor (1) invades lymphatics,
blood vessels, or pleura or (2) contains tumor necrosis. It is
understood that lepidic growth can occur in metastatic tumors
and invasive mucinous adenocarcinomas. Nevertheless, the spe-
cific term “Lepidic predominant adenocarcinoma (LPA)” in this
classification defines a nonmucinous adenocarcinoma that has
lepidic growth as its predominant component, and these tumors
are now separated from invasive mucinous adenocarcinoma.
The term LPA should not be used in the context of invasive
mucinous adenocarcinoma with predominant lepidic growth.
In the categories of mixed subtype in the 1999/2004
WHO classifications and type C in the Noguchi classifica-
tion,4,46 there was no assessment of the percentage of lepidic
growth (former BAC pattern), so in series diagnosed accord-
ing to these classification systems, most of the LPAs are
buried among a heterogeneous group of tumors that include
predominantly invasive adenocarcinomas. Nevertheless, sev-
eral studies have shown lepidic growth to be associated with
more favorable survival in small solitary resected lung ade-
nocarcinomas with an invasive component.47,64,103–105 One
recent study of stage I adenocarcinomas using this approach
demonstrated 90% 5-year recurrence free survival.44
Pathology Recommendation 6
For nonmucinous adenocarcinomas previously classi-
fied as mixed subtype where the predominant subtype con-
sists of the former nonmucinous BAC, we recommend use of
the term LPA and discontinuing the term “mixed subtype”
(strong recommendation, low-quality evidence).
Acinar predominant adenocarcinoma shows a majority
component of glands, which are round to oval shaped with a
central luminal space surrounded by tumor cells (Figure 6D).4
The neoplastic cells and glandular spaces may contain mucin.
Acinar structures also may consist of rounded aggregates of
tumor cells with peripheral nuclear polarization with central
cytoplasm without a clear lumen. AIS with collapse may be
difficult to distinguish from the acinar pattern. Nevertheless,
when the alveolar architecture is lost and/or myofibroblastic
stroma is present, invasive acinar adenocarcinoma is consid-
ered present. Cribriform arrangements are regarded as a
pattern of acinar adenocarcinoma.106
Papillary predominant adenocarcinoma shows a major
component of a growth of glandular cells along central
fibrovascular cores (Figure 6E).4 This should be distinguished
from tangential sectioning of alveolar walls in AIS. If a tumor
has lepidic growth, but the alveolar spaces are filled with
papillary structures, the tumor is classified as papillary ade-
nocarcinoma. Myofibroblastic stroma is not needed to diag-
nose this pattern.
Micropapillary predominant adenocarcinoma has tumor
cells growing in papillary tufts, which lack fibrovascular cores
(Figure 6F).4 These may appear detached and/or connected to
alveolar walls. The tumor cells are usually small and cuboidal
with minimal nuclear atypia. Ring-like glandular structures may
“float” within alveolar spaces. Vascular invasion and stromal
invasion are frequent. Psammoma bodies may be seen.
The micropapillary pattern of lung adenocarcinoma
was cited in the 2004 WHO classification in the discussion,4
but there were too few publications on this topic to introduce
it as a formal histologic subtype.107–109 Although most of the
studies have used a very low threshold for classification of
adenocarcinomas as micropapillary, including as low as 1 to
5%,108,109 it has recently been demonstrated that tumors
classified as micropapillary according to the predominant
subtype also have a poor prognosis similar to adenocarcino-
mas with a predominant solid subtype.44 All articles on the
topic of micropapillary lung adenocarcinoma in early-stage
patients have reported data indicating that this is a poor
prognostic subtype.95,108–119 Additional evidence for the ag-
gressive behavior of this histologic pattern is the overrepre-
sentation of the micropapillary pattern in metastases com-
pared with the primary tumors, where it sometimes comprises
only a small percentage of the overall tumor.43
Pathology Recommendation 7
In patients with early-stage adenocarcinoma, we rec-
ommend the addition of “micropapillary predominant adeno-
carcinoma,” when applicable, as a major histologic subtype
due to its association with poor prognosis (strong recommen-
dation, low-quality evidence).
Solid predominant adenocarcinoma with mucin produc-
tion shows a major component of polygonal tumor cells forming
sheets, which lack recognizable patterns of adenocarcinoma, i.e.,
acinar, papillary, micropapillary, or lepidic growth (Figure 6G).4
If the tumor is 100% solid, intracellular mucin should be present
in at least five tumor cells in each of two high-power fields,
confirmed with histochemical stains for mucin (Figure 6H).4
Solid adenocarcinoma must be distinguished from squamous
cell carcinomas and large cell carcinomas both of which may
show rare cells with intracellular mucin.
Variants
Rationale for Changes in Adenocarcinoma
Histologic Variants
Rationale for separation of invasive mucinous adenocarci-
noma (formerly mucinous BAC) from nonmucinous adeno-
carcinomas. Multiple studies indicate that tumors formerly
classified as mucinous BAC have major clinical, radi-
ologic, pathologic, and genetic differences from the tumors
formerly classified as nonmucinous BAC (Table
4).55,77,120,121,125–127,136,145–148 In particular, these tumors show a
very strong correlation with KRAS mutation, whereas nonmuci-
nous adenocarcinomas are more likely to show EGFR mutation
and only occasionally KRAS mutation (Table 4). Therefore, in
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the new classification, these tumors are now separated into
different categories (Table 1). The neoplasms formerly termed
mucinous BAC, now recognized to have invasive components in
the majority of cases, are classified as invasive mucinous ade-
nocarcinoma (formerly mucinous BAC).149
Rationale for including mucinous cystadenocarcinoma in
colloid adenocarcinoma. Tumors formerly classified as
“Mucinous cystadenocarcinoma” are very rare, and they
probably represent a spectrum of colloid adenocarcinoma.
Therefore, we suggest that these adenocarcinomas that con-
sist of uni- or oligolocular cystic structures by imaging and/or
gross examination be included in the category of colloid
adenocarcinoma.150 For such tumors, a comment could be
made that the tumor resembles that formerly classified as
mucinous cystadenocarcinoma.
Rationale for removing clear cell and signet ring carcinoma
as adenocarcinoma subtypes. Clear cell and signet ring cell
features are now regarded as cytologic changes that may
occur in association with multiple histologic patterns.151,152
Thus, their presence and extent should be recorded, but data are
not available that show a clinical significance beyond a strong
association with the solid subtype. They are not considered to be
specific histologic subtypes, although associations with molec-
ular features are possible such as the recent observation of a
solid pattern with more than 10% signet ring cell features in up
to 56% of tumors from patients with echinoderm microtubule-
associated protein-like 4 (EML4) and anaplastic lymphoma ki-
nase (ALK) gene fusions (EML4-ALK).153
Rationale for adding enteric adenocarcinoma. Enteric ad-
enocarcinoma is added to the classification to draw attention
to this rare histologic type of primary lung adenocarcinoma
that can share some morphologic and immunohistochemical
features with colorectal adenocarcinoma.154 Because of these
similarities, clinical evaluation is needed to exclude a gastro-
intestinal primary. It is not known whether there are any
distinctive clinical or molecular features.
Histologic Features
Invasive mucinous adenocarcinoma (formerly muci-
nous BAC) has a distinctive histologic appearance with tumor
cells having a goblet or columnar cell morphology with
abundant intracytoplasmic mucin (Figures 7A, B). Cytologic
atypia is usually inconspicuous or absent. Alveolar spaces
often contain mucin. These tumors may show the same
heterogeneous mixture of lepidic, acinar, papillary, micro-
papillary, and solid growth as in nonmucinous tumors. The
clinical significance of reporting semiquantitative estimates
of subtype percentages and the predominant histologic sub-
type similar to nonmucinous adenocarcinomas is not certain.
When stromal invasion is seen, the malignant cells may show
less cytoplasmic mucin and more atypia. These tumors differ
from mucinous AIS and MIA by one or more of the following
criteria: size (3 cm), amount of invasion (0.5 cm), mul-
FIGURE 7. Invasive mucinous adenocarcinoma. A, This area
of invasive mucinous adenocarcinoma demonstrates a pure
lepidic growth. The tumor consists of columnar cells filled
with abundant mucin in the apical cytoplasm and shows
small basal oriented nuclei. B, Nevertheless, elsewhere this
tumor demonstrated invasion associated with desmoplastic
stroma and an acinar pattern.
TABLE 4. Difference between Invasive Mucinous Adenocarcinoma and Nonmucinous Adenocarcinoma In Situ/Minimally
Invasive Adenocarcinoma/Lepidic Predominant Adenocarcinoma
Invasive Mucinous Adenocarcinoma
(Formerly Mucinous BAC)
Nonmucinous AIS/MIA/LPA
(Formerly Nonmucinous BAC)
Female 49/84 (58%)52,120–123 101/140 (72%)52,120–123
Smoker 39/87 (45%)52,120–122,124 75/164 (46%)52,120–122,124
Radiographic appearance Majority consolidation; air bronchogram125 Majority ground-glass attenuation23,56,58,103,129–134
Frequent multifocal and multilobar presentation56,125–128
Cell type Mucin-filled, columnar, and/or goblet50–52,125,135 Type II pneumocyte and/or Clara cell50–52,125,135
Phenotype
CK7 Mostly positive (88%)a54,55,136–139 Positive (98%)a54,55,136–139
CK20 Positive (54%)a54,55,136–139 Negative (5%)a54,55,136–139
TTF-1 Mostly negative (17%)1a54,55,120,137–139 Positive (67%)a54,55,120,137–139
Genotype
KRAS mutation Frequent (76%)a55,94,121,127,140–144 Some (13%)a55,121,127,140–144
EGFR mutation Almost none (3)a55,121,127,140–142 Frequent (45%)a55,121,127,140–142
a Numbers represent the percentage of cases that are reported to be positive.
BAC, bronchioloalveolar carcinoma; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LPA, lepidic predominant adenocarcinoma; EGFR, epidermal
growth factor receptor; TTF, thyroid transcription factor.
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tiple nodules, or lack of a circumscribed border with miliary
spread into adjacent lung parenchyma.
There is a strong tendency for multicentric, multilobar,
and bilateral lung involvement, which may reflect aerogenous
spread. Mixtures of mucinous and nonmucinous tumors may
rarely occur; then the percentage of invasive mucinous ade-
nocarcinoma should be recorded in a comment. If there is at
least 10% of each component, it should be classified as
“Mixed mucinous and nonmucinous adenocarcinoma.” Inva-
sive mucinous adenocarcinomas (formerly mucinous BAC)
need to be distinguished from adenocarcinomas that produce
mucin but lack the characteristic goblet cell or columnar cell
morphology of the tumors that have historically been classi-
fied as mucinous BAC. When mucin is identified by light
microscopy or mucin stains in adenocarcinomas that do not
meet the above criteria, this feature should be reported in a
comment after classifying the tumor according to the appro-
priate terminology and criteria proposed in this classification.
This can be done by adding a descriptive phrase such as “with
mucin production” or “with mucinous features” rather than
the term “invasive mucinous adenocarcinoma.”
Pathology Recommendation 8
For adenocarcinomas formerly classified as mucinous
BAC, we recommend they be separated from the adenocar-
cinomas formerly classified as nonmucinous BAC and de-
pending on the extent of lepidic versus invasive growth that
they be classified as mucinous AIS, mucinous MIA, or for
overtly invasive tumors “invasive mucinous adenocarci-
noma” (weak recommendation, low-quality evidence).
Colloid adenocarcinoma shows extracellular mucin in
abundant pools, which distend alveolar spaces with destruc-
tion of their walls (Figure 8A). The mucin pools contain
clusters of mucin-secreting tumor cells, which may comprise
only a small percentage of the total tumor and, thus, be
inconspicuous (Figure 8A).155,156 The tumor cells may consist
of goblet cells or other mucin secreting cells. Colloid adeno-
carcinoma is found more often as a mixture with other
adenocarcinoma histologic subtypes rather than as a pure
pattern. A tumor is classified as a colloid adenocarcinoma
when it is the predominant component; the percentages of
other components should be recorded.150 Cystic gross and
histologic features are included in the spectrum of colloid
adenocarcinoma, but in most cases, this is a focal feature.
Cases previously reported as mucinous cystadenocarcinoma
are extremely rare, and now these should be classified as
colloid adenocarcinoma with cystic changes. The cysts are
filled with mucin and lined by goblet or other mucin secreting
cells (Figure 8B). The lining epithelium may be discontinu-
ous and replaced with inflammation including a granuloma-
tous reaction or granulation tissue. Cytologic atypia of the
neoplastic epithelium is usually minimal.157
Fetal adenocarcinoma consists of glandular elements
with tubules composed of glycogen-rich, nonciliated cells
that resemble fetal lung tubules (Figure 8C).4 Subnuclear
vacuoles are common and characteristic. Squamoid morules
may be seen within lumens. Most are low grade with a
favorable outcome. High-grade tumors occur. When mixtures
occur with other histologic subtypes, the tumor should be
classified according to the predominant component.158 This
tumor typically occurs in younger patients than other adeno-
carcinomas. Uniquely, these tumors appear driven by muta-
tions in the beta-catenin gene, and the epithelial cells express
aberrant nuclear and cytoplasmic staining with this antibody
by immunohistochemistry.159,160 Nakatani et al. and Sekine et
al.159,160 have suggested that up-regulation of components in
the Wnt signaling pathway such as -catenin is important in
low-grade fetal adenocarcinomas and in biphasic pulmonary
blastomas in contrast to high-grade fetal adenocarcinomas.
Enteric differentiation can occur in lung adenocarci-
noma, and when this component exceeds 50%, the tumor is
classified as pulmonary adenocarcinoma with enteric differ-
entiation. The enteric pattern shares morphologic and immu-
nohistochemical features with colorectal adenocarcinoma.154
In contrast to metastatic colorectal adenocarcinoma, these
tumors are histologically heterogeneous with some compo-
nent that resembles primary lung adenocarcinoma such as
lepidic growth. Recording of the percentages of these other
components may be useful. The enteric pattern consists of
glandular and/or papillary structures sometimes with a crib-
riform pattern, lined by tumor cells that are mostly tall-
FIGURE 8. Adenocarcinoma, variants. A, Colloid adenocar-
cinoma consists of abundant pools of mucin growing within
and distending airspaces. Focally well-differentiated muci-
nous glandular epithelium grows along the surface of fibrous
septa and within the pools of mucin. Tumor cells may be
very inconspicuous. B, This colloid adenocarcinoma contains
a cystic component surrounded by a fibrous wall that is
filled with pools of mucin; such a pattern was previously
called mucinous cystadenocarcinoma. The surface of the fi-
brous wall is lined by well-differentiated cuboidal or colum-
nar mucinous epithelium. C, Fetal adenocarcinoma consists
of malignant glandular cells growing in tubules and papillary
structures. These tumor cells have prominent clear cyto-
plasm, and squamoid morules are present. D, Enteric adeno-
carcinoma consists of an adenocarcinoma that morphologi-
cally resembles colonic adenocarcinoma with back-to-back
angulated acinar structures. The tumor cells are cuboidal to
columnar with nuclear pseudostratification.
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columnar with nuclear pseudostratification, luminal necrosis,
and prominent nuclear debris (Figure 8D).154 Poorly differ-
entiated tumors may have a more solid pattern. These tumors
show at least one immunohistologic marker of enteric differ-
entiation (CDX-2, CK20, or MUC2). Consistent positivity for
CK7 and expression of TTF-1 in approximately half the cases
helps in the distinction from metastatic colorectal adenocar-
cinoma.154,161 CK7-negative cases may occur.162 Primary
lung adenocarcinomas that histologically resemble colorectal
adenocarcinoma but lack immunohistochemical markers of
enteric differentiation are probably better regarded as lung
adenocarcinomas with enteric morphology rather than pul-
monary adenocarcinoma with enteric differentiation.163
CLASSIFICATION FOR SMALL BIOPSIES AND
CYTOLOGY
Clinical Relevance of Histologic Diagnosis
Drives Need to Classify NSCLC Further
This section applies to pathologic diagnosis of the
majority of patients with lung cancer due to presentation with
locally advanced or metastatic disease. Because of the need
for improved separation of squamous cell carcinoma from
adenocarcinoma, as it determines eligibility for molecular
testing and impacts on specific therapies, there is now greater
clinical interest in application of additional pathology tools to
refine further the diagnosis in small biopsies (bronchoscopic,
needle, or core biopsies) and cytology specimens from pa-
tients with advanced lung cancer, when morphologic features
are not clear.30,39,40,164,165 Patients with adenocarcinoma
should be tested for EGFR mutations (see evidence in Clin-
ical Recommendation section) because patients with EGFR
mutation-positive tumors may be eligible for first-line TKI
therapy.8–11 Adenocarcinoma patients are also eligible for
pemetrexed12–15 or bevacizumab-based chemotherapy regi-
mens (see Clinical Recommendation section).16,17
Pathology Recommendation 9
For small biopsies and cytology, we recommend that
NSCLC be further classified into a more specific histologic
type, such as adenocarcinoma or squamous cell carcinoma,
whenever possible (strong recommendation, moderate quality
evidence).
Data Driving Need to Classify NSCLC Further
are Based Only on Light Microscopy
All current data that justify the importance of the
distinction between histologic types of NSCLC in patients
with advanced lung cancer are based on light microscopy
alone.8–16 Thus, the diagnosis for clinical work, research
studies, and clinical trials should be recorded in a manner, so
it is clear how the pathologist made their determination:
based on light microscopy alone or light microscopy plus
special studies.
Pathology Consideration for Good Practice
1. When a diagnosis is made in a small biopsy or cytol-
ogy specimen in conjunction with special studies, it
should be clarified whether the diagnosis was estab-
lished based on light microscopy alone or whether
special stains were required.
Management of Tissue for Molecular Studies is
Critical
Strategic use of small biopsy and cytology samples is
important, i.e., use the minimum specimen necessary for an
accurate diagnosis, to preserve as much tissue as possible for
potential molecular studies (Figure 9).166 Methods that use
substantial amounts of tissue to make a diagnosis of adeno-
carcinoma versus squamous cell carcinoma, such as large
panels of immunohistochemical stains or molecular studies,
may not provide an advantage over routine light microscopy
with a limited immunohistochemical workup.165
Pathology Consideration for Good Practice
2. Tissue specimens should be managed not only for
diagnosis but also to maximize the amount of tissue
available for molecular studies.
3. To guide therapy for patients with advanced lung
adenocarcinoma, each institution should develop a
multidisciplinary team that coordinates the optimal
approach to obtaining and processing biopsy/cytology
specimens to provide expeditious diagnostic and mo-
lecular results.
If Light Microscopic Diagnosis is Clearly
Adenocarcinoma or Squamous Cell Carcinoma,
Use These WHO Diagnostic Terms
Squamous cell carcinoma and adenocarcinoma should
be diagnosed on biopsy and cytological materials when the
criteria for specific diagnosis of these tumor types in the 2004
WHO classification are met. Nevertheless, for tumors that do
not meet these criteria, newly proposed terminology and
criteria are outlined in Table 2 and Figure 9.4
Histologic Heterogeneity of Lung Cancer is an
Underlying Complexity
Because of histologic heterogeneity, small biopsy
and/or cytology samples may not be representative of the
total tumor, and there may be a discrepancy with the final
histologic diagnosis in a resection specimen. Still, combined
histologic types that meet criteria for adenosquamous carci-
noma comprise less than 5% of all resected NSCLCs.4 A
much more common difficulty in small biopsies or cytologies
is classifying poorly differentiated tumors where clear differ-
entiation is difficult or impossible to appreciate on light
microscopy. The heterogeneity issue also makes it impossible
to make the diagnosis of AIS, MIA, large cell carcinoma, or
pleomorphic carcinoma in a small biopsy or cytology, be-
cause resection specimens are needed to make these interpre-
tations. The term “large cell carcinoma” has been used in
some clinical trials, but the pathologic criteria for that diag-
nosis are not defined, and it is not clear how these tumors
were distinguished from NSCLC-NOS, as this diagnosis
cannot be made in small biopsies or cytology, the type of
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FIGURE 9. Algorithm for adenocarcinoma diagnosis in small biopsies and/or cytology. Step 1: When positive biopsies (fiber-
optic bronchoscopy [FOB], transbronchial [TBBx], core, or surgical lung biopsy [SLBx]) or cytology (effusion, aspirate, wash-
ings, and brushings) show clear adenocarcinoma (ADC) or squamous cell carcinoma (SQCC) morphology, the diagnosis can
be firmly established. If there is neuroendocrine morphology, the tumor may be classified as small cell carcinoma (SCLC) or
non-small cell lung carcinoma (NSCLC), probably large cell neuroendocrine carcinoma (LCNEC) according to standard criteria
(  positive,   negative, and   positive or negative). If there is no clear ADC or SQCC morphology, the tumor is re-
garded as NSCLC-not otherwise specified (NOS). Step 2: NSCLC-NOS can be further classified based on (a) immunohisto-
chemical stains (b) mucin (DPAS or mucicarmine) stains, or (c) molecular data. If the stains all favor ADC: positive ADC mark-
er(s) (i.e., TTF-1 and/or mucin positive) with negative SQCC markers, then the tumor is classified as NSCLC, favor ADC. If
SQCC markers (i.e., p63 and/or CK5/6) are positive with negative ADC markers, the tumor is classified as NSCLC, favor
SQCC. If the ADC and SQCC markers are both strongly positive in different populations of tumor cells, the tumor is classified
as NSCLC-NOS, with a comment it may represent adenosquamous carcinoma. If all markers are negative, the tumor is classi-
fied as NSCLC-NOS. See text for recommendations on NSCLCs with marked pleomorphic and overlapping ADC/SQCC mor-
phology. †EGFR mutation testing should be performed in (1) classic ADC, (2) NSCLC, favor ADC, (3) NSCLC-NOS, and (4)
NSCLC-NOS, possible adenosquamous carcinoma. In a NSCLC-NOS, if EGFR mutation is positive, the tumor is more likely to
be ADC than SQCC. Step 3: If clinical management requires a more specific diagnosis than NSCLC-NOS, additional biopsies
may be indicated (-ve  negative; ive  positive; TTF-1: thyroid transcription factor-1; DPAS ve: periodic-acid-Schiff with
diastase; ve: positive; e.g., IHC, immunohistochemistry; NE, neuroendocrine; CD, cluster designation; CK, cytokeratin; NB,
of note). EGFR, epidermal growth factor receptor; DPAS, diastase-periodic acid Schiff.
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specimens used to diagnose the patients with advanced-stage
lung cancer studied in these trials.13,15,167
Pathology Considerations for Good Practice
4. The terms AIS or MIA should not be diagnosed in
small biopsies or cytology specimens. If a noninvasive
pattern is present in a small biopsy, it should be
referred to as a lepidic growth pattern.
5. The term large cell carcinoma should not be used for
diagnosis in small biopsy or cytology specimens and
should be restricted to resection specimens where the
tumor is thoroughly sampled to exclude a differenti-
ated component.
Use Minimal Stains to Diagnose NSCLC, Favor
Adenocarcinoma, or Favor Squamous Cell
Carcinoma
In those cases where a specimen shows NSCLC lacking
either definite squamous or adenocarcinoma morphology,
immunohistochemistry may refine diagnosis (Figure 9, step
2). To preserve as much tissue as possible for molecular
testing in small biopsies, the workup should be minimal.165
Realizing that new markers are likely to be developed, we
suggest the initial evaluation use as only one adenocarcinoma
marker and one squamous marker. At the present time, TTF-1
seems to be the single best marker for adenocarcinoma.
TTF-1 provides the added value of serving as a pneumocyte
marker that can help confirm a primary lung origin in 75 to
85% of lung adenocarcinomas.69,168,169 This can be very
helpful in addressing the question of metastatic adenocarci-
noma from other sites such as the colon or breast. Diastase-
periodic acid Schiff or mucicarmine mucin stains may also be
of value. p63 is consistently reported as a reliable marker for
squamous histology and CK5/6 also can be useful.39,40,170–176
Cytokeratin 7 also tends to stain adenocarcinoma more often
than squamous cell carcinoma.177 Other antibodies (34E12
and S100A7) are less specific and sensitive for squamous
differentiation. These data have been confirmed using resec-
tions where biopsies were interpreted as NSCLC39 and also
work on most needle aspirate specimens.40 It is possible that
cocktails of nuclear and cytoplasmic markers (TTF-1/CK5/6
or p63/napsin-A) may allow for use of fewer immunohisto-
chemical studies of multiple antibodies.164 Cases positive for
an adenocarcinoma marker (i.e.,TTF-1) and/or mucin with a
negative squamous marker (i.e., p63) should be classified as
“NSCLC favor adenocarcinoma” (Figures 10A–C) and those
that are positive for a squamous marker, with at least mod-
erate, diffuse staining, and a negative adenocarcinoma marker
and/or mucin stains, should be classified as “NSCLC favor
squamous cell carcinoma,” with a comment specifying
whether the differentiation was detected by light microscopy
and/or by special stains. These two small staining panels are
generally mutually exclusive. If an adenocarcinoma marker
such as TTF-1 is positive, the tumor should be classified as
NSCLC, favor adenocarcinoma despite any expression of
squamous markers.164,165 If the reactivity for adenocarcinoma
versus squamous markers is positive in a different population
of tumor cells, this may suggest adenosquamous carcinoma.
If tumor tissue is inadequate for molecular testing, there may
be a need to rebiopsy the patient to perform testing that will
guide therapy (step 3, Figure 9).
There may be cases where multidisciplinary correlation
can help guide a pathologist in their evaluation of small
biopsies and/or cytology specimens from lung adenocarcino-
mas. For example, if a biopsy showing NSCLC-NOS is
obtained from an Asian, female, never smoker with ground-
glass nodules (GGNs) on CT, the pathologist should know
this information as the tumor is more likely to be adenocar-
cinoma and have an EGFR mutation.
Cytology is a Useful Diagnostic Method,
Especially When Correlated with Histology
Cytology is a powerful tool in the diagnosis of lung
cancer, in particular in the distinction of adenocarcinoma
from squamous cell carcinoma.178 In a recent study, of 192
preoperative cytology diagnoses, definitive versus favored
versus unclassified diagnoses were observed in 88% versus
8% versus 4% of cases, respectively.179 When compared with
subsequent resection specimens, the accuracy of cytologic
diagnosis was 93% and for definitive diagnoses, it was 96%.
For the adenocarcinoma and squamous cell carcinoma cases,
only 3% of cases were unclassified, and the overall accuracy
was 96%. When immunohistochemistry was used in 9% of
these cases, the accuracy was 100%.179
Whenever possible, cytology should be used in con-
junction with histology in small biopsies (Figure 10D).40,180
FIGURE 10. Adenocarcinoma in small biopsy and cytology.
Poorly differentiated non-small cell carcinoma, favor adeno-
carcinoma. A, This core biopsy shows a solid pattern of
growth, and morphologically, it lacks any acinar, papillary,
or lepidic patterns. The mucin stain was also negative. B,
The TTF-1 stain is strongly positive. C, The p63 stain is very
focally positive. The strongly and diffusely positive TTF-1 and
only focal p63 staining favor adenocarcinoma. In this case,
EGFR mutation was positive. D, Cytology from different ade-
nocarcinoma shows large malignant cells with abundant cy-
toplasm and prominent nuclei growing in an acinar struc-
ture. EGFR, epidermal growth factor receptor; TTF, thyroid
transcription factor.
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In another study where small biopsies were evaluated in
conjunction with cytology for the diagnosis of adenocarci-
noma versus squamous cell carcinoma versus unclassified
(NSCLC-NOS), the result for cytology was 70% versus 19%
versus 11% and for biopsies, it was 72%, 22%, and 6%,
respectively.180 Still when cytology was correlated with bi-
opsy, the percentage of cases diagnosed as NSCLC-NOS was
greatly reduced to only 4% of cases.180 In a small percentage
of cases (5%), cytology was more informative than histol-
ogy in classifying tumors as adenocarcinoma or squamous
cell carcinoma.180 The factors that contributed the greatest to
difficulty in a specific diagnosis in both studies were poor
differentiation, low specimen cellularity, and squamous his-
tology.179,180
Pathology Consideration for Good Practice
6. When paired cytology and biopsy specimens exist,
they should be reviewed together to achieve the most
specific and nondiscordant diagnoses.
Preservation of Cell Blocks from Cytology
Aspirates or Effusions for Molecular Studies
The volume of tumor cells in biopsies may be small due
to frequent prominent stromal reactions, so that there may be
insufficient material for molecular analysis. Material derived
from aspirates or effusions may have more tumor cells than a
small biopsy obtained at the same time, so any positive
cytology samples should be preserved as cell blocks, so that
tumor is archived for immunohistochemical and molecular
studies. Furthermore, these materials should be used judi-
ciously in making the diagnosis to preserve as much material
as possible for potential molecular studies.40,181–183 In a re-
cent study, material from cell blocks prepared from 128 lung
cancer cytology specimens was suitable for molecular anal-
ysis for EGFR and KRAS mutations in 126 (98%) of speci-
mens.179
Pathology Consideration for Good Practice
7. Cell blocks should be prepared from cytology samples
including pleural fluids.
NSCLC-NOS: If No Clear Differentiation by
Morphology or Immunohistochemistry
There will remain a minority of cases where the diag-
nosis remains NSCLC-NOS, as no differentiation can be
established by routine morphology and/or immunohistochem-
istry (Figure 9, step 2). In the setting of a tumor with a
negative adenocarcinoma marker (i.e., TTF-1), and only
weak or focal staining for a squamous marker, it is best to
classify the tumor as NSCLC-NOS rather than NSCLC, favor
squamous cell carcinoma. These cases may benefit from
discussion in a multidisciplinary setting (a) to determine the
need for a further sample if subtyping will affect treatment;
(b) whether molecular data should be sought, again if treat-
ment will be defined by such data; (c) whether noninvasive
features such as imaging characteristics (e.g., peripheral
GGN supporting adenocarcinoma) favor a tumor subtype;
and (d) whether clinical phenotype (e.g., female, never
smoker, and Asian) may assist in determining future man-
agement (Figure 9, step 3).
Pathology Recommendation 10
We recommend that the term NSCLC-NOS be used as
little as possible, and we recommend it be applied only when
a more specific diagnosis is not possible by morphology
and/or special stains (strong recommendation, moderate qual-
ity evidence).
Pathology Consideration for Good Practice
8. The term nonsquamous cell carcinoma should not be
used by pathologists in diagnostic reports. It is a
categorization used by clinicians to define groups of
patients with several histologic types who can be
treated in a similar manner; in small biopsies/cytology,
pathologists should classify NSCLC as adenocarci-
noma, squamous cell carcinoma, NSCLC-NOS, or
other terms outlined in Table 2 or Figure 9.
NSCLC-NOS: When Morphology and
Immunohistochemistry are Conflicting
Rarely, small samples may show either morphologic
features of both squamous cell carcinoma and adenocarci-
noma with routine histology or by immunohistochemical
expression of both squamous and adenocarcinoma markers;
these should be termed as “NSCLC-NOS” with a comment
recording the features suggesting concurrent glandular and
squamous cell differentiation, specifying whether this was
detected by light microscopy or immunohistochemistry. As
p63 expression can occur in up to one third of adenocarci-
nomas,40,184,185 in a tumor that lacks squamous cell morphol-
ogy, virtually all tumors that show coexpression of p63 and
TTF-1 will be adenocarcinomas. It is possible that the tumor
may be an adenosquamous carcinoma but that diagnosis
cannot be established without a resection specimen showing
at least 10% of each component. If TTF-1 and p63 positivity
are seen in different populations of tumor cells, it is possible
that this may be more suggestive of adenosquamous carci-
noma than if these markers are coexpressed in the same tumor
cells.
Interpret Morphologic and Staining Patterns
to Maximize Patient Eligibility for Therapies
Presently, the recommendation for EGFR mutation
testing and candidacy for pemetrexed or bevacizumab ther-
apy is for the diagnosis of (1) adenocarcinoma, (2) NSCLC-
NOS, favor adenocarcinoma, or (3) NSCLC-NOS (see Clin-
ical Recommendation section later). For this reason, in most
NSCLC, the primary decision pathologists need to focus on,
while interpreting small biopsies and cytology specimens,
whether the tumor is a definite squamous cell carcinoma or
NSCLC, favor squamous cell carcinoma versus one of the
above diagnoses. Thus, when morphology or immunohisto-
chemical findings are equivocal, pathologists need to keep in
mind that a diagnosis of squamous cell carcinoma or NSCLC,
favor squamous cell carcinoma will exclude them from his-
tologically driven molecular testing or chemotherapy. In such
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a situation, it may be best to favor NSCLC-NOS, to allow the
patient to be eligible for the therapeutic options mentioned
earlier in the text. Hopefully, effective therapies, perhaps
based on molecular targets, will become available for squa-
mous cell carcinoma in the near future.
Pathology Consideration for Good Practice
9. The above strategy for classification of adenocarci-
noma versus other histologies and the terminology in
Table 2 and Figure 9 should be used in routine diag-
nosis and future research and clinical trials, so that
there is uniform classification of disease cohorts in
relationship to tumor subtypes and data can be strati-
fied according to diagnoses made by light microscopy
alone versus diagnoses requiring special stains.
Distinction of Adenocarcinoma from
Sarcomatoid Carcinomas
Cases that show sarcomatoid features such as marked
nuclear pleomorphism, malignant giant cells, or spindle cell
morphology should be preferentially regarded as adenocarci-
noma or squamous cell carcinoma if these features are clearly
present, as this is apt to influence management. Nevertheless,
pleomorphic carcinoma, carcinosarcoma, and blastoma are
very difficult to diagnose in small specimens due to the
limited ability to assess for mixed histologies. Nevertheless,
if a small biopsy shows what is probably an adenocarcinoma
with pleomorphism, a comment should be made, e.g.,
“NSCLC, favor adenocarcinoma, with giant and/or spindle
cell features” (depending on which feature is identified).
Pathology Consideration for Good Practice
10. Tumors that show sarcomatoid features, such as
marked nuclear pleomorphism, malignant giant cells,
or spindle cell morphology, should be preferentially
regarded as adenocarcinoma or squamous cell carci-
noma if clear glandular or squamous features are
present, as this is apt to influence management. If such
features are not present, the term “poorly differentiated
non-small cell carcinoma with giant and/or spindle cell
features” (depending on what feature is present)
should be used.
Distinction of Adenocarcinoma from
Neuroendocrine Carcinomas
Some cases of NSCLC may suggest neuroendocrine
(NE) morphology; these should be assessed with NE markers
(CD56, chromogranin, and/or synaptophysin), so that a diag-
nosis of large cell NE carcinoma (LCNEC) can be suggested.
The term NSCLC, possible LCNEC is usually the best term
when this diagnosis is suspected as it is difficult to establish
a diagnosis of LCNEC on small biopsies. In those lacking NE
morphology, we recommend against using routine staining
with NE markers, as immunohistochemical evidence of NE
differentiation in otherwise definite adenocarcinoma and
squamous cell carcinoma does not seem to affect progno-
sis186,187 or treatment.
Pathology Consideration for Good Practice
11. NE immunohistochemical markers should only be per-
formed in cases where there is suspected NE morphol-
ogy. If NE morphology is not suspected, NE markers
should not be performed.
GRADING OF ADENOCARCINOMAS
No well-established histologic or cytologic grading
system exists for lung adenocarcinoma. Most publications
which grade adenocarcinomas do not cite specific morpho-
logic criteria. The overall grade of a tumor is typically
determined by the component with the worst grade. Only a
few studies have evaluated detailed morphologic grading
systems.41,188–191 The primary approaches are based on archi-
tectural and/or nuclear attributes. Nevertheless, the following
histologic features are promising candidates for components
of a grading system. By architecture, the following prognostic
associations have been reported: poor (solid41,43,44,53,69 and
micropapillary),43,44,108,109 favorable (nonmucinous lepi-
dic43,44,46,192 [formerly BAC]), and intermediate (papillary
and acinar).43,44 Thus, comprehensive histologic subtyping
method and subclassification of invasive tumors by the pre-
dominant subtype may be a simple way to develop the
architectural grade of lung adenocarcinomas,43,44 similar to
the Gleason grading system for prostate cancer.193 By nuclear
criteria, preliminary data suggest poor prognosis may be
associated with large nuclei and variability in nuclear size and
shape.190,191,194 As stated earlier in the text, histologic grading
should not be confused with the GRADE method of formu-
lating recommendations and weighing evidence.190,191
STRATEGIC USE OF PATHOLOGIC SPECIMENS
FOR MOLECULAR STUDIES
With the emerging importance of molecular diagnostics
to guide therapy, a multidisciplinary approach is needed to set
a consistent strategy for obtaining and preserving tissue
samples optimized to perform studies such as DNA sequence
analysis, fluorescence in situ hybridization (FISH), and, in
some settings, RNA-based studies. It is not yet possible to
provide specific guidelines on how to do this in the current
document because of the wide variation in infrastructure and
expertise from one institution to another. Still, this process
begins with the method of obtaining tissue (fine needle
aspiration [FNA], core or transbronchial biopsy, and surgical
resection) and continues with the processing of the specimen
in the pathology department, to delivery of material for
molecular analysis, and communication of the molecular
results in pathology reports.
If a portion of a sampled tumor is snap frozen for
molecular studies, a few considerations exist as regards
resection specimens. As most critical molecular studies can
be performed from formalin-fixed paraffin-embedded tissue,
there is a need for frozen samples only for certain techniques
such as comparative genomic hybridization (CGH) and gene
expression profiling. If frozen tissue is being obtained from
tumors with lepidic predominant tumors where AIS or MIA
is in the differential diagnosis, efforts should be made to
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ascertain whether this frozen piece has an invasive compo-
nent. The CT and gross appearance of the lesion should be
considered to ensure a solid component is sampled in a tumor
that appeared part solid on CT. Another approach is to
perform a frozen section from the tissue saved for storage in
a freezer.
Small biopsies and/or cytologic samples including pleural
fluids can be used for many molecular analyses.179,181,183,195–205
EGFR mutation testing and KRAS mutation testing are readily
performed on these specimens.179–181,195–199,203–205 Formalin-
fixed paraffin-embedded samples can be used effectively for
polymerase chain reaction-based mutation testing and for FISH
or chromogenic in situ hybridization (CISH) testing for gene
amplification and for immunohistochemistry. Cytology smears
can be analyzed for immunohistochemical and certain molecu-
lar studies, but it is far preferable if cell blocks are available.
Manual or laser-guided microdissection may enrich tumor
cells for molecular studies. Assessment of EGFR mutations
helps in selecting patients to be treated with EGFR-TKIs.
Molecular testing in the setting of clinical trials can stratify
patients by results of gene expression or markers of sensitiv-
ity to specific cytotoxic agents such as excision repair cross-
complementation group 1 or breast cancer 1 for platinum,
ribonucleotide reductase M1 for gemcitabine or thymidylate
synthase for antifolates.206–211
Summary of Pathology Recommendations
1. We recommend discontinuing the use of the term
“BAC” (strong recommendation, low-quality evi-
dence).
2. For small (3 cm), solitary adenocarcinomas with
pure lepidic growth, we recommend the term “Adeno-
carcinoma in situ” that defines patients who should
have 100% disease-specific survival, if the lesion is
completely resected (strong recommendation, moder-
ate quality evidence). Remark: Most AIS are nonmu-
cinous, rarely are they mucinous.
3. For small (3 cm), solitary, adenocarcinomas with
predominant lepidic growth and small foci of invasion
measuring 0.5 cm, we recommend a new concept of
“Minimally invasive adenocarcinoma” to define pa-
tients who should have near 100%, disease-specific
survival, if completely resected (strong recommenda-
tion, low-quality evidence). Remark: Most MIA are
nonmucinous, rarely are they mucinous.
4. For invasive adenocarcinomas, we suggest compre-
hensive histologic subtyping be used to assess histo-
logic patterns semiquantitatively in 5% increments,
choosing a single predominant pattern. We also sug-
gest that individual tumors be classified according to
the predominant pattern and that the percentages of the
subtypes be reported (weak recommendations and
low-quality evidence).
5. In patients with multiple lung adenocarcinomas, we
suggest comprehensive histologic subtyping in the
comparison of the complex, heterogeneous mixtures of
histologic patterns to determine whether the tumors
are metastases or separate synchronous or metachro-
nous primaries (weak recommendation, low-quality
evidence).
6. For nonmucinous adenocarcinomas previously classi-
fied as mixed subtype where the predominant subtype
consists of the former nonmucinous BAC, we recom-
mend use of the term LPA and discontinuing the term
“mixed subtype” (strong recommendation, low-quality
evidence).
7. In patients with early-stage adenocarcinoma, we rec-
ommend the addition of “micropapillary predominant
adenocarcinoma,” when applicable, as a major histo-
logic subtype due to its association with poor progno-
sis (strong recommendation, low-quality evidence).
8. For adenocarcinomas formerly classified as mucinous
BAC, we recommend that they be separated from the
adenocarcinomas formerly classified as nonmucinous
BAC and depending on the extent of lepidic versus
invasive growth that they be classified as mucinous
AIS, mucinous MIA, or for overtly invasive tumors
“invasive mucinous adenocarcinoma” (weak recom-
mendation, low-quality evidence).
9. For small biopsies and cytology, we recommend that
NSCLC be further classified into a more specific type,
such as adenocarcinoma or squamous cell carcinoma,
whenever possible (strong recommendation, moderate
quality evidence).
10. We recommend that the term NSCLC-NOS be used as
little as possible, and we recommend it be applied only
when a more specific diagnosis is not possible by
morphology and/or special stains (strong recommen-
dation, moderate quality evidence).
Summary of Pathology Considerations for Good
Practice
1. When a diagnosis is made in a small biopsy or cytol-
ogy specimen in conjunction with special studies, it
should be clarified whether the diagnosis was estab-
lished based on light microscopy alone or whether
special stains were required.
2. Tissue specimens should be managed not only for
diagnosis but also to maximize the amount of tissue
available for molecular studies.
3. To guide therapy for patients with advanced lung
adenocarcinoma, each institution should develop a
multidisciplinary team that coordinates the optimal
approach to obtaining and processing biopsy/cytology
specimens to provide expeditious diagnostic and mo-
lecular results.
4. The terms AIS or MIA should not be used in small
biopsies or cytology specimens. If a noninvasive pat-
tern is present in a small biopsy, it should be referred
to as lepidic growth.
5. The term large cell carcinoma should not be used for
diagnosis in small biopsy or cytology specimens and
should be restricted to resection specimens where the
tumor is thoroughly sampled to exclude a differenti-
ated component.
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6. When paired cytology and biopsy specimens exist,
they should be reviewed together to achieve the most
specific and nondiscordant diagnoses.
7. Cell blocks should be prepared from cytology samples
including pleural fluids.
8. The term nonsquamous cell carcinoma should not be
used by pathologists in diagnostic reports. It is a
categorization used by clinicians to define groups of
patients with several histologic types who can be
treated in a similar manner; in small biopsies/cytology,
pathologists should classify NSCLC as adenocarci-
noma, squamous cell carcinoma, NSCLC-NOS, or
other terms outlined in Table 2 or Figure 9.
9. The above strategy for classification of adenocarci-
noma versus other histologies and the terminology in
Table 2 and Figure 9 should be used in routine diag-
nosis and future research and clinical trials, so that
there is uniform classification of disease cohorts in
relationship to tumor subtypes and data can be strati-
fied according to diagnoses made by light microscopy
alone versus diagnoses requiring special stains.
10. Tumors that show sarcomatoid features, such as
marked nuclear pleomorphism, malignant giant cells,
or spindle cell morphology, should be preferentially
regarded as adenocarcinoma or squamous cell carci-
noma if clear glandular or squamous features are
present, as this is apt to influence management. If such
features are not present, the term “poorly differentiated
non-small cell carcinoma with giant and/or spindle cell
features” (depending on what feature is present)
should be used.
11. NE immunohistochemical markers should only be per-
formed in cases where there is suspected NE morphol-
ogy. If NE morphology is not suspected, NE markers
should not be performed.
Pathology Research Recommendations
1. Criteria for MIA are based on limited published data
and require further validation. Persistent questions
include what is the optimal method for measuring the
size of the invasive component? Is 0.5 cm the best size
cut off? If multiple areas of invasion are present,
should the greatest dimension of the largest invasive
focus be used or the total size multiplied times the
percentage of the invasive components? What should
be the impact of scar size or prominent stromal des-
moplasia and stromal inflammation on determining
size of the invasive component? Should criteria for
MIA be different for mucinous versus nonmucinous
tumors?
2. Lepidic growth may also be composed of neoplastic
cells with nuclear atypia resembling that of the adja-
cent invasive patterns. Whether there is any clinical
implication is unknown. That is, it is not established if
this is in situ or invasive carcinoma.
3. The level of reproducibility for identifying predomi-
nant histologic patterns is untested. In particular, how
should the lepidic pattern be distinguished from other
invasive patterns such as acinar and papillary?
4. Do tumors that meet criteria for MIA have 100%
disease-free survival if the invasive component is
predominantly solid, micropapillary or if they show
giant cell and spindle cell components that fail to
qualify for a diagnosis pleomorphic carcinoma?
5. What is the long-term follow-up for completely re-
sected solitary mucinous MIA? Can this be the initial
presentation for multifocal invasive mucinous adeno-
carcinoma?
6. Does the micropapillary pattern have a similar poor
prognostic significance in advanced stage and early
stage?
7. Is there any prognostic significance to the aggressive
micropapillary or solid components when present in
relatively small amounts if they do not represent the
predominant pattern? If so, what percentage is needed
for such significance?
8. Is immunohistochemical testing using EGFR muta-
tion-specific antibodies a reliable method for predict-
ing the presence of an EGFR mutation?
9. It is unknown whether there is any added value pro-
vided by refining NSCLC-NOS via immunohisto-
chemistry on small biopsies or cytology samples. This
requires assessment in future trials using systemic
therapy.
10. Additional markers for squamous or adenocarcinoma
differentiation, such as desmocoglein-3212 or desmo-
collin213 for squamous cell carcinoma or napsin-A for
adenocarcinoma,214 need further evaluation.
11. The ability of pathologists to distinguish AIS from
invasive disease at frozen section is not proven.
12. Currently, we cannot recommend any specific grading
system. Further investigation is needed to determine
whether the optimal grading system should include
architectural versus nuclear assessment or both.
13. In specimens from metastatic sites, is there any clinical
significance to recognizing histologic patterns, includ-
ing the predominant pattern?
CLINICAL FEATURES
Several important clinical facts have had a significant
impact on this classification: (1) adenocarcinoma histology is
a strong predictor for outcome to pemetrexed therapy in
advanced-stage patients.13–15 (2) Distinction between adeno-
carcinoma or other non-small cell histologies and squamous
cell carcinoma is important because of potential life-threat-
ening hemorrhage in patients with squamous cell carcinoma
who receive bevacizumab therapy.16 (3) EGFR mutation is a
validated predictive marker for response and progression-free
survival (PFS) with EGFR-TKIs in the first-line therapy in
advanced lung adenocarcinoma.8,215–218 (4) Molecular mark-
ers are an important evolving area in evaluation and manage-
ment of patients with lung adenocarcinoma.219 More data are
needed regarding other molecular markers beyond EGFR
mutation, such as KRAS mutation, EGFR gene copy number,
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and EML4-ALK fusion, before they can be accepted as vali-
dated markers for a recommendation in this document.153,220
Biopsy and Pathology Issues for the Clinician
After initial evaluation, a plan for an invasive proce-
dure to obtain a diagnosis and complete staging should be
made in a multidisciplinary setting.221 The site for the biopsy
should be chosen to yield the maximal information with the
least risk. A key element in determining the type of procedure
is the need to obtain adequate tissue for all pathologic and
molecular evaluations (e.g., mutation analysis and immuno-
histochemistry).
For sampling a peripheral nodular lesion that contains a
solid component, the suitable invasive procedures are trans-
thoracic biopsy such as CT-guided biopsies, bronchoscopy/
navigation-assisted bronchoscopy, sublobar resection, or lo-
bectomy (e.g., by video-assisted thoracic surgery, VATS, or
thoracoscopy). Either a core biopsy or a FNA with a cell
block will reliably obtain adequate tissue.179,203 For medias-
tinal involvement, sampling can be achieved by blind TBNA,
endobronchial endoscopy (endobronchial ultrasound) -guided
TBNA, EUS-guided FNA, mediastinoscopy, VATS, or
Chamberlain procedure. For patients with recurrent disease,
repeat biopsy can be useful not only to confirm the diagnosis
but also the molecular profile.
Prognostic and Predictive Factors
Multiple clinical, pathologic, and molecular factors
have been explored for their association with patient out-
come. To facilitate the discussion, we divided them into two
categories although both categories are prognostic factors in
the strict sense: prognostic factors, which dictate the viru-
lence of the disease (e.g., progression and recurrence), and
predictive factors, which are correlated with the outcome for
specific therapies. Predictive and prognostic factors may
overlap; however, they are often different.
The main independent clinical prognostic factors for
patients with lung adenocarcinoma are stage, performance
status, age, and sex.222 The independent prognostic value of
stage exists whether using clinical223 or pathological224 stag-
ing. Data also suggest that smoking history may be an
independent prognostic factor.225
Although clinical factors provide important prognostic
information, recently there has been greater focus on predic-
tive factors for specific therapies, initially focusing on histol-
ogy.219 In early clinical trials of erlotinib and gefitinib, some
patients with good responses to these drugs were those with
adenocarcinoma with lepidic growth patterns (formerly
known as BAC).226 This led to trials of gefitinib and erlotinib
in patients formerly diagnosed with BAC. West et al.227
reported the results of a Southwest Oncology Group trial in
which 17% of patients had a response to gefitinib. Similarly,
Miller et al.198 reported a 22% response rate to erlotinib in
patients formerly diagnosed with BAC or adenocarcinoma
with BAC features. In the new classification, many of these
tumors would be regarded to be invasive adenocarcinomas
with varying degrees of lepidic growth.
Although histology will continue to play an important
predictive role, recently the use of molecular markers for
predicting response to therapy has become more prominent,
particularly after the discovery of EGFR mutations and their
association with sensitivity to erlotinib and gefitinib.215–217,219
Although KRAS mutations were identified in patients with
NSCLC more than 20 years ago, their clinical role as predic-
tive and prognostic biomarkers remains controversial. Sev-
eral phase 2 clinical trials228–233 verified use of EGFR muta-
tions as predictors of response to erlotinib and gefitinib.
EGFR mutations occur most frequently in East Asian patients
and in those patients with little or no smoking history. The
EGFR mutations that are most common and recognized to be
of greatest clinical significance are somatic point mutations in
codon L858R in exon 21 and in-frame deletions in exon
19.215–217,219 Four recent phase 3 trials were based on patients
with either pure or predominantly lung adenocarcinoma his-
tology; one which selected patients clinically and three which
selected patients by EGFR mutations have demonstrated that
patients with EGFR mutation lung cancer have better treat-
ment outcomes (response rate and PFS) when treated with the
EGFR inhibitor gefitinib than with conventional platin-based
doublet chemotherapy.8–11 In the Iressa Pan Asian Survival
Study trial, molecular subset analysis showed that PFS ben-
efit was limited to the patients with EGFR mutation (hazard
ratio [HR]: 0.48, 95% confidence interval [CI]: 0.36–0.64)
and that gefitinib therapy was detrimental for those without
mutations (HR: 2.85, 95% CI: 2.05–3.98).8 Maemondo et
al.10 showed PFS of patients with EGFR mutations was 10.8
months in patients who received gefitinib compared with 5.4
months in those who received carboplatin plus paclitaxel
(HR: 0.30, 95% CI: 0.22–0.41, p  0.001) and a higher
response rate (73.7% versus 30.7%, p 0.001). Mitsudomi et
al.9 showed that patients with EGFR mutations who received
gefitinib had significantly longer median PFS of 9.2 months
versus 6.3 months (HR: 0.489, 95% CI: 0.336–0.710, p 
0.001). Zhou et al.11 showed that patients with EFGR mutations
treated with erlotinib have significantly longer median PFS of
13.1 months compared with 4.6 months for those treated with
gemcitabine/carboplatin (HR: 0.16, 95% CI: 0.10–0.26, p 
0.0001). These trials do not demonstrate significant differences
in overall survival for gefitinib treatment, likely an effect of
cross-over treatment with gefitinib or erlotinib in second-
line therapy. Similarly, in a chemotherapy-controlled
phase III study (INTEREST) comparing gefitinib with
docetaxel, EGFR mutation-positive patients had longer
PFS and higher objective response rates (42% versus 7%)
than those without mutations for gefitinib.234 The finding
that EGFR mutation is predictive of important benefit for
PFS and responsiveness to TKI therapy is also supported
by multiple phase 2 clinical trials.228–233
Other molecular predictors of outcome have also been
explored for erlotinib and gefitinib treatment. Retrospective
analysis of data from the Iressa Survival Evaluation in Lung
Cancer study showed that EGFR copy number and protein
expression were predictive of significantly better overall
survival after treatment with gefitinib.235 A multivariate anal-
ysis of data from the Canadian BR.21, phase 3 randomized,
placebo-controlled trial of erlotinib in advanced NSCLC
showed that EGFR copy number (but not EGFR mutation
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status) was associated with worse survival (HR: 1.9, 95% CI:
1.1–3.4) and a better response to erlotinib (p  0.005), after
controlling for race, performance status, weight loss, smoking
history, prior treatment, and response to prior treatment.236
In a second-line, chemotherapy controlled phase III study
(INTEREST) comparing gefitinib with docetaxel, overall sur-
vival was similar in the two arms, and there were no statistically
significant interactions between treatment and EGFR copy num-
ber, protein expression, or mutation status.234 The results of all
three of these studies may be influenced by inclusion of large
numbers of patients with histologies other than adenocarcinoma
and should be regarded as exploratory.234–236
For treatment of advanced NSCLC, response and out-
come to EGFR-TKIs have been demonstrated in most studies
to be better predicted by EGFR mutation testing rather than
copy number or immunohistochemistry. In a phase II study of
erlotinib-treated patients, multivariate analysis of molecular
predictors showed that EGFR mutations, but not copy num-
ber, was predictive of response to erlotinib with a response of
83% in patients with EGFR mutations versus 7% in those
without (p  0.01).198 In this study, immunohistochemistry
was not predictive of response.198 Another study by Sholl et
al.237 found EGFR mutation status, but not FISH, CISH, or
immunohistochemistry, was useful for predicting response
and PFS for TKI therapy. The recent development of new
mutation-specific antibodies for EGFR exon 19 deletion
and L858R mutation seems to be much more reliable in
predicting EGFR mutation status, and these need to be
evaluated in future clinical trials.238–240 In the Iressa Pan
Asian Survival Study, in FISH patients, gefitinib was
worse than chemotherapy if those patients lacked EGFR
mutations.241 All these studies used RECIST to measure
response to therapy.8–11,198,234–236,241
More recently, investigators have noted that all NSCLC
histologies other than squamous cell carcinoma seem to
garner more benefit from two drugs, pemetrexed for efficacy
and bevacizumab for avoidance of toxicity. Nevertheless,
most of the analyses are subgroup analyses with the known
shortcomings. Pemetrexed, a multitargeted antifolate agent,
seems to have greater activity in NSCLCs with nonsquamous
histology (adenocarcinoma and NSCLC-NOS), with the
greatest proportion of benefit observed in patients with ade-
nocarcinomas as demonstrated in two phase 3 trials.12–15 In a
phase 3 trial, comparing cisplatin/pemetrexed with cisplatin/
gemcitabine, preplanned subgroup analysis, revealed median
overall survival was significantly better for patients with
adenocarcinoma (12.6 versus 10.9 months, HR  0.81, 95%
CI: 0.71–0.99, p  0.03) and large cell carcinoma (would be
called NSCLC-NOS by the current proposal), overall survival
of 10.4 versus 6.7 months (HR  0.67; CI: 0.48–0.96),
whereas no benefit was seen with squamous cell carcinoma or
with all histologies combined.13 Follow-up analysis of the
same patients from this phase 3 study but focusing on those
without grade 3 or 4 drug toxicity, a similar benefit for overall
survival was found in patients with nonsquamous histology
comparing cisplatin pemetrexed with cisplatin/gemcitabine
(median survival of 5.6 months versus 2.8 months, respec-
tively, HR  0.64, 95% CI: 0.56–0.72, p  0.001).12
Ciuleanu et al. showed in a phase 3 trial comparing pem-
etrexed versus placebo, where prespecified analysis for his-
tology were performed, that patients with adenocarcinoma
histology had better median PFS (4.5 versus 1.5 months,
HR 0.511; CI: 0.38–0.68; p 0.0001) and median overall
survival (16.8 versus 11.5 months; HR  0.73; CI: 0.56–
0.96; p  0.026). The benefit was also significant for
nonsquamous carcinomas classified as other, and for
nonsquamous cell carcinoma overall, but not for large cell
carcinomas or squamous cell carcinomas.14 Several phase II
studies have also shown a benefit for pemetrexed in patients
with advanced NSCLC with nonsquamous histologic sub-
types.242,243 Nevertheless, a recent phase III trial, with pri-
mary end point as the assessment of quality of life, observed
similar outcomes for patients treated with pemetrexed/carbo-
platin regardless of histology.244 Patients with adenocarci-
noma or NSCLC-NOS (nonsquamous NSCLC histology) are
the only patients who have been demonstrated to benefit from
bevacizumab in combination with chemotherapy.245 Indeed,
patients with squamous cell carcinoma are at greater risk of
adverse events, and therefore, such patients have been ex-
cluded from receiving this drug by the Food and Drug
Administration,17 but they are eligible for adjuvant therapy in
ongoing trials.16
Very recently, a new predictive biomarker has been
identified in patients with NSCLC, the EML4/ALK transloca-
tion. This translocation leads to an oncogenic constitutive
activation of ALK.220,246,247 A recent study of 82 patients
with NSCLC confirmed to have ALK fusion by FISH dem-
onstrated a 57% overall response rate to crizotinib (PF-
02341066), an inhibitor of MET and ALK, and the estimated
6-month PFS was 72%.248 De novo resistance mutations in
the kinase domain of EML4-ALK have been reported to
develop during ALK inhibitor therapy.249
Clinical Implications of Histology and Molecular
Testing
Accurate histologic subtyping and EGFR mutation test-
ing are important and should be included in the initial
work-up of patients with advanced lung adenocarcinoma
because it may guide treatment decisions. Whether other
EGFR tests should be recommended (i.e., immunohistochemis-
try and FISH) and/or KRAS mutation as an indicator of TKI
resistance is not yet clear.250,251 In addition to EGFR mutation
analysis, additional molecular tests are in development and may
be more useful when further clinical data support their use.
Surgically Resectable NSCLC
Twenty to 30% of patients with NSCLC are diagnosed
with stage I to stage IIIA disease and, thus, may be amenable
to surgical resection. Patients who undergo resection have
differing prognoses based on pathologic stage. The recent
IASLC staging project has demonstrated overall 5-year sur-
vival of 73% for stage IA, 58% for stage IB, 46% for stage
IIA, 36% for stage IIB, 24% for stage IIIA, and 9% for stage
IIIB.252,253 The introduction of adjuvant cisplatin-based che-
motherapy represented a major step forward with a 5%
increase in cure rate.254 Still, 27% of patients with stage IA
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disease and 42% of patients with stage IB NSCLC eventually
recur and die of their disease; there is no accurate way to
predict which of these patients have poor-risk disease and are
likely to recur. Similarly, 41% of patients with stage II
NSCLC are cured by surgery alone and do not need any
adjuvant therapy.252,253 Thus, an urgent need to identify
factors, which will select patients for adjuvant therapy, exists.
Several predictive factors for better efficacy of adjuvant
chemotherapy have been described in retrospective analyses
of phase III randomized adjuvant studies. An example is low
expression of the DNA repair genes excision repair cross-
complementation group 1 for greater benefit from cisplatin-
based chemotherapy, although this needs further valida-
tion.207 Based on initial data showing striking differences in
survival predicted by histologic subtyping according to this
proposed classification of lung adenocarcinomas in resected
specimens,44 it is possible in the future that histology will
play an important role in selecting patients for adjuvant
therapy.
Clinical Recommendation
In patients with advanced lung adenocarcinoma, we
recommend testing for EGFR mutation (strong recommenda-
tion, moderate quality evidence).
Remarks: This is a strong recommendation because
potential benefits clearly outweigh harms. This recommenda-
tion assumes that correct classification by EGFR mutation
status is associated with important benefit based on random-
ized phase 3 clinical trials of EGFR-TKI therapy, which
demonstrate a predictive benefit for response rate and PFS,
but not overall survival, and subset analyses of multiple
additional studies.
Clinical Consideration for Good Practice
1. If molecular testing is planned, appropriate biopsy
methods should be used to obtain sufficient tissue for
both pathologic diagnosis and molecular analyses, and
the specimens should be handled appropriately.
Clinical Research Recommendations
1. How can this histological and/or molecular classifica-
tion improve our ability to estimate prognosis and
optimize the selection of patients for a specific therapy?
2. What is the relative importance of histologic versus
molecular data for identifying prognostic or predictive
markers based on small biopsies and cytology versus
resected specimens?
3. Is immunohistochemical testing using EGFR mutation-
specific antibodies as predictive of response to EGFR-
TKIs as EGFR mutations?
4. In advanced lung adenocarcinomas, are the prognostic
and therapeutic implications of histology any different
if the pathologic diagnosis is based on a combination of
histology and immunohistochemistry (i.e., TTF-1
and/or p63) versus conventional light microscopy alone
which is the basis for current data?
5. In metastatic lung adenocarcinomas, what are the clin-
ical implications of any potential differences in molec-
ular or histologic features compared with primary tu-
mors?
6. What are the clinical, epidemiological, molecular, and
histologic characteristics of never smokers with lung
adenocarcinoma?
MOLECULAR FEATURES
There are several molecular observations that have
important implications for lung adenocarcinoma patients: (1)
EGFR mutation is a validated predictive marker for response
and PFS with EGFR-TKIs in the first-line therapy in ad-
vanced lung adenocarcinoma.8,215–218 (2) Tumors with an
EGFR mutation have been associated with a more indolent
course.8,234 (3) EGFR and KRAS mutations are virtually
mutually exclusive.236,255 (4) EGFR/KRAS mutation-negative
cases may have detectable fusion of EML4-ALK.153,220
Histogenetic Origins of Lung Adenocarcinoma
Subtypes
Normal lung tissues, from which lung cancers arise, can
be anatomically divided into two major components, the
air-conducting system and the peripheral lung parenchyma
where gases are exchanged. After generation of the two
embryologic lung buds, repeated branching morphogenesis
results in conducting airways and the subsequent develop-
ment of the terminal sac and alveoli. During the later stages,
the regulatory TTF-1 is ubiquitously expressed in the periph-
eral lung epithelial cells such as small bronchioles and alve-
oli.256 TTF-1 is potentially a lineage-specific survival onco-
gene of some lung adenocarcinomas.257,258 The peripheral
bronchioloalveolar compartment (terminal bronchioles, alve-
olar ducts, and alveoli) also contains two potential tumor cells
of origin, the Clara cells and type II pneumocytes,259 which
together comprise the terminal respiratory unit (TRU) and
give rise to tumors expressing TTF-1. These often manifest as
a GGN on CT. The central conducting airways (bronchi) contain
two potential candidate progenitor cells that give rise to tumors:
the bronchial basal cells and the mucous cells.259,260 These
tumors are TTF-1 negative and demonstrate a solid appearance
on CT. Hierarchical clustering analysis of lung adenocarcinoma
based on the expression profile demonstrated two major clusters,
which correspond to TRU and non-TRU-type adenocarcinomas
and thus two major subsets of adenocarcinoma with distinct
histogenetic origins.261
It is hypothesized that a subset of lung adenocarcino-
mas undergoes progression from AAH to AIS to invasive
carcinoma and that this may be a stepwise process triggered
by multiple genetic changes that supplement those responsi-
ble for initiation of the malignant phenotype.4,77,262,263 Al-
though EGFR and KRAS mutations are observed from the
earliest stages including normal epithelium264,265 and AAH,
to invasive adenocarcinoma, EGFR gene copy number
changes become widespread later at the stage of invasion and
metastases.266,267 EGFR, KRAS, and TTF-1 amplification are
characteristic of this progression.258,266,268 p53 mutation is
more often found in invasive compared with noninvasive
adenocarcinomas.48,269–273 Nevertheless, p53 mutation has
not been identified as a reliable prognostic marker or a
therapeutic target.
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Histologic Molecular Correlations
High-throughput analysis of DNA mutations has re-
shaped the molecular landscape of lung adenocarcinomas.98
DNA sequencing of 623 known cancer-related genes in 188
adenocarcinomas identified 1013 somatic mutations.98 In ad-
dition to confirmation of known tumor suppressor genes p53,
P16INK4, and STK11/LKB1, newly described mutations in
NF1 and RB1 were detected at a frequency of 10% each.
There were two other important findings: (1) mutations were
often detected in the tyrosine kinase gene family members
EGFR, KRAS, ERBB4, EPHA4, EPH3, KDR, and FGFR4
that are potentially targetable by tyrosine-kinase inhibitors
and (2) mutual exclusivity was demonstrated in several gene
mutation pairs including EGFR/KRAS, EGFR/STK11, and
NF1 and p53/ATM.98,274 Mutation frequency showed negative
correlations between acinar, papillary, and BAC subtypes
with mutations in LRP1B, p53, and INHBA.98 Nevertheless,
these mutations showed significant positive correlations with
the solid subtype (Table 5).98
Many publications have studied the prevalence and
specificity of KRAS and EGFR alterations in lung adenocar-
cinoma (Table 5). The frequency of KRAS and EGFR muta-
tions is each 10 to 30% with higher EGFR mutation fre-
quency in Asians, never smokers, and nonmucinous tumors,
whereas KRAS mutations are most common in non-Asians,
smokers, and in invasive mucinous adenocarcinoma.140 Mu-
TABLE 5. Adenocarcinoma Histologic Subtypes, Molecular, and Radiological Associations
Histological Subtype
Predominant Molecular Features CT Scan Appearance Gene Pathways Associated References
Nonmucinous AIS and
MIA
TTF-1  (100%) GGN, part-solid nodule Not known 141, 261, 275–277
EGFR mutation never smokers: 10–30%
KRAS mutation smokers: 10–30%
Lepidic (nonmucinous) TTF-1  (100%) Part solid nodule Low cell cycle stimulatory278 69, 261, 266, 276, 279–283
EGFR mutation never smokers: 10–30% GGN or solid nodule High Wnt
EGFR amplification: 20–50%
KRAS mutation smokers: 10%
BRAF mutations: 5%
Papillary TTF-1  (90–100%) Solid nodule Low cell cycle278 stimulatory 69, 98, 264, 266, 279, 280–282,
284–286EGFR mutation: 10–30%
EGFR amplification: 20–50% High EGFR
KRAS mutation 3% (lack of KRAS) High notch
ERBB2 mutations: 3%
p53 mutations: 30%
BRAF mutations: 5%
Acinar TTF-1  or  Solid nodule High PDGF278 69, 98, 269, 287
KRAS mutation in smokers (20%) Low EGFR
EGFR mutations 10% nonsmokers Low angiogenesis
EGFR amplification: 10%
EML4/ALK translocation: 5%
P53 mutations: 40%
Micropapillary KRAS mutations (33%) Unknown Unknown 69, 95, 283
EGFR mutations (20%)
BRAF mutations (20%)
Solid TTF-1 (70%) Solid High cell cycle
stimulatory278
69, 98, 125, 269, 287, 288
MUC1 positive High angiogenesis
KRAS mutation smokers: 10–30% High JAK-STAT
EGFR mutation never smokers: 10–30% Low notch
EGFR amplification: 20–50%
EML4/ALK translocation 5%
p53 mutation: 50%
LRP1B mutations
INHBA mutations
Invasive mucinous
adenocarcinoma
TTF-1 (0–33% positive) Consolidation, air
bronchograms; less
often GGO
Not known 123, 125, 126, 137, 140–142,
286, 289–291KRAS mutation: 80–100%
No EGFR mutation
MUC5 MUC6 MUC2
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; GGN, ground-glass nodule; EGFR, epidermal growth factor receptor; TTF, thyroid transcription factor.
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tations in EGFR mainly affect the adenosinetriphosphate-
binding pocket within the tyrosine kinase domain. The most
common mutations result in an arginine for leucine substitu-
tion at amino acid 858 and in-frame deletions at exon 19.
EGFR mutation status has been reported to be significantly
associated with AIS, LPA, papillary, and micropapillary
adenocarcinoma subtypes, although EGFR mutations can be
seen in tumors with other histologic subtypes (Table 5). A
large cohort of 806 NSCLC specimens showed a correlation
between the presence of EGFR mutation and adenocarcino-
mas formerly classified as BAC or with BAC features (prob-
ably including AIS, MIA, and LPA),275 but another study
with pathology review of 97 adenocarcinomas showed no
difference.274 Predominant solid subtype has been shown to
be significantly associated with KRAS mutations288 but not in
all studies.69 V600E BRAF mutations, occur in less than 5%
of cases, and they have been associated with papillary,
micropapillary, and lepidic components of invasive lung
adenocarcinomas.95,279 Other less common types of BRAF
mutations are reported such as V599E in a patient with a
“well differentiated adenocarcinoma” (no subtyping informa-
tion)292 and two cases with missense mutations in exon 11
(G465V) and in exon 15 (L596R) where no histologic sub-
typing was reported.293
Table 5 summarizes our present knowledge on the
molecular features associated with predominant patterns of
adenocarcinoma. The only example of a strong correlation
between a histologic subtype and a set of molecular and
biologic features is that of invasive mucinous adenocarci-
noma (former mucinous BAC), which typically have KRAS
mutations and lack of EGFR mutation.55,140,141–144 Most of
these tumors are negative for TTF-1, and they may express
MUC 2-5-6 because of their derivation from bronchiolar
mucinous goblet cells.146,289
EGFR mutation is a specific target for therapy by
EGFR-TKIs and is a validated biomarker of treatment re-
sponse based on three recent phase 3 trials (see detailed
explanation in Clinical Recommendation section)8–11 and
multiple phase 2 trials.228–233 Recently described mutation-
specific antibodies for the EGFR exon 19 deletion and L858R
mutation seem to be much more reliable in predicting EGFR
mutation status than previous antibodies, but they require further
testing and validation in clinical trials.238–240 Specific acquired
EGFR mutations such as T790M as well as, other genetic
alterations in MET (amplification), ERBB3 (overexpression),
and epiregulin (autocrine loop activation), account for approxi-
mately 50% of cases of TKI resistance.236,250,294–299
Lung Cancers with ALK Translocations
A minority of lung tumors harbor a small inversion
within chromosome 2p giving rise to the transforming fusion
gene EML4-ALK. No activating mutations in the kinase
domain are observed; the dimerization of the fusion protein
causes its activation.246 Epidemiological characteristics in-
clude prevalence in 5% of lung adenocarcinomas. Younger
age, male gender, and never or light smokers may identify a
population of patients with greater chance of harboring this
aberration.153,220,248,300 A variety of histologic features are
reported including acinar, papillary, cribriform, mucin pro-
duction (intra- and extracytoplasmic), and signet-ring pat-
terns.153,220,300–304
It is still at issue whether other histological types such
as squamous cell carcinoma and mucoepidermoid carcinoma
also contain EML4-ALK translocations. Detection of the
EML4-ALK translocations can be difficult and can be ap-
proached with several methods including immunohistochem-
istry, FISH, and reverse transcription-polymerase chain reac-
tion.153,248,249,300–303,305 Immunohistochemistry requires use
of antibodies and methods that are validated to correspond
well to EML4-ALK translocations, and it may serve as a
useful screening method.153,302,306–308 Most tumors with
EML4-ALK translocations are positive for TTF-1 and may be
p63 positive.301,303 Tumors with EML4-ALK translocations
seem to be mutually exclusive with EGFR and KRAS muta-
tions and have a lower frequency of p53 muta-
tions.153,247,300,301,303 Another ALK translocation involving
KIF5B-ALK fusion has been recently identified in lung ade-
nocarcinomas; however, at present, insufficient data exist to
define its specific histological nature.302 De novo resistance
mutations in the kinase domain of EML4-ALK have been
reported to develop during ALK inhibitor therapy.249
Lung Adenocarcinoma Gene Expression
Analyses
The messenger RNA genomic profiling of tumors can
provide important information about pathogenesis, patient
prognosis, and prediction of response to therapy in a
fashion that complements histological evaluation. Unsu-
pervised clustering analysis consistently shows three dis-
tinct groups of adenocarcinomas associated with tumor
morphology69,261,309,310 and with lung developmental path-
ways. Beer et al.309 showed that tumors within the three
clusters were significantly correlated with differentiation,
stage, and morphology as classified by bronchial-derived
or lepidic morphology. Borczuk et al.310 showed that inva-
sive features were associated with the cluster containing more
aggressive tumors. The three groups consisted of noninvasive
and minimally invasive tumors (5 mm); mixed-invasive
and lepidic pattern tumors; and solid-invasive cancers. Motoi
et al.69 demonstrated that the three clusters correlated strongly
with former BAC, solid, and papillary subtypes, respectively.
Takeuchi et al.261 showed that expression profile-defined
adenocarcinoma subtypes were correlated with morphology
and with normal lung developmental pathways. Morphologic
analysis revealed two branches consisted of TRU-type ade-
nocarcinomas, which are based on lepidic pattern and expres-
sion of TTF-1 and surfactant proteins, and non-TRU adeno-
carcinomas that lack these characteristics. TRU tumors were
further divided into TRU-a and TRU-b classes. Functional
annotation showed retention of normal peripheral differenti-
ated lung features in the TRU types, which contrasted with
the cell cycling and proliferation enriched annotation of genes
associated with the non-TRU tumors.
Although EGFR mutations are found in association
with papillary predominant adenocarcinomas (Table 5)69,98
and TRU-a tumors, whereas KRAS mutations are more fre-
quent in the solid and TRU-b tumors, it is clear that oncogene
mutation status is not a primary determinant of the molecular
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subtypes as defined by gene expression profiling.311 Taken
together, unsupervised clustering defines three morphologi-
cally distinct groups of lung adenocarcinomas. These include
(1) AIS and MIA; (2) invasive nonsolid adenocarcinoma; and
(3) invasive adenocarcinoma, predominantly solid.69,261,309,310
Thus, these molecular profiles provide biological plausibility
for the proposed classification scheme that creates separate
categories based on evaluation of lepidic pattern and other
components, including solid pattern.
Recently Bryant et al.278 used the lung adenocarcinoma
gene expression data from Shedden et al.99 together with
complete pathological review to examine associations be-
tween 27 known cancer-related pathways and the adenocar-
cinoma subtype, clinical characteristics, and patient survival.
Unsupervised clustering of adenocarcinoma and gene expres-
sion enrichment analysis reveals three main clusters and that
cell proliferation is the most important pathway separating
tumors into subgroups.278 Further, adenocarcinomas with
increased cell proliferation demonstrate significantly poorer
outcome and an increased solid subtype component. Interest-
ingly, tumors with any solid component have decreased
survival, when compared with tumors without a solid com-
ponent. Significant associations between specific histologic
subtypes, gene expression pathways, and clusters were also
reported, some of these are included in Table 5. The consis-
tency of these findings was demonstrated using two indepen-
dent lung adenocarcinoma cohorts from Japan (N  87) and
France (N  89) using the identical analytic procedures.278
Tumor messenger RNA profiling is emerging as a
source of clinically significant information regarding patient
outcome after resection. Several predictors have been devel-
oped based on methodologically sound approaches that in-
clude independent validation.312–324 The results of these stud-
ies are heterogeneous in terms of the number of genes both in
the predictors and in the specific genes included in each
signature. This heterogeneity is expected given differences in
study design, assay platform, tumor histology, and patient
selection. A large, multicenter, blinded evaluation of eight
independently derived genomic signatures of prognosis in
442 adenocarcinomas demonstrated that the addition of clin-
ical covariates enhanced the performance of the signatures,
relative to using gene expression alone.99 A method that
relied on the correlated expression of 100 gene clusters to
predict subject outcome produced relatively good perfor-
mance with several other methods showing similar perfor-
mance.99 Relatively higher expression of a cluster of 545
genes enriched for cell proliferation was associated with poor
outcome. This study is a model for the careful handling of
challenges inherent in translational cancer genomic studies
and for its vast repository of clinical and pathologically
annotated data. Independent prospective evaluation of the
predictive accuracy of these signatures, prospective clinical
trials, and application to small biopsy specimens200–203 will
be required to extend this area of research.
Copy Number Analyses of Lung
Adenocarcinoma Subtypes
Multiple studies have defined lung adenocarcinoma
subtypes by using techniques to assess DNA copy number
changes.41,69,257,280,284,325–327 Adenocarcinoma subtype was
examined in a comprehensive analysis using CGH by Aviel-
Ronen et al.,326 who contrasted former BAC and invasive
mixed-type adenocarcinoma with former BAC features, most
of which would probably be classified as invasive adenocar-
cinoma with predominant lepidic growth in the new classifi-
cation. A large number of specific chromosomal alterations
were detected such as gain at 1p, 2q, 5p, 7p, 11p, 11q, 12q,
16p, 16q, 17q, 20q, and 21q in both former BAC and the
adenocarcinomas with lepidic growth. Although both types
had similar chromosomal changes, the invasive adenocarci-
nomas with lepidic growth showed greater variability and
frequency of chromosomal changes and with longer segmen-
tal alterations and deletions. Deletions were also more com-
mon in adenocarcinomas with lepidic growth and were ob-
served mainly on 3p and 5q and to a lesser extent on 4q and
6q. The genomic profile of former BAC seems to be distin-
guishable from that of invasive adenocarcinoma with lepidic
growth, with the latter displaying greater genomic aberra-
tions. This demonstrates a progression at the genomic level
from former BAC to the invasive areas of adenocarcinoma
with lepidic growth.
Weir et al.257 found the most common focal amplifica-
tion event in lung adenocarcinoma involved chromosome
14q13.3 in 12% of cases and TTF-1, also known as NKX2-1
was identified in this region. Barletta et al.41 examined his-
tologic correlations with amplification of the TTF-1 gene, and
six cases demonstrated TTF-1 amplification among the 49
acinar, papillary, and solid subtypes but not in tumors clas-
sified formerly as BAC.
EGFR gene amplification was examined using FISH by
Hirsch et al.,284 who demonstrated that EGFR gene copy
number detected by FISH is associated with improved re-
sponse to gefitinib therapy in patients with advanced-stage
former BAC and in adenocarcinomas with lepidic growth. A
strong relationship between mutation and EGFR amplifica-
tion was also reported by Cappuzzo et al.328 Conde et al.280
reported similar results with a higher percentage of mutations
among adenocarcinomas with former BAC and papillary
morphologies relative to adenocarcinomas without these fea-
tures. Chang et al.327 used CISH and found that TKI respon-
siveness was significantly associated with EGFR mutation
and adenocarcinoma morphology but only marginally with
increased EGFR gene copy number. Other studies report
similar findings, but the relationship between adenocarci-
noma subtype and EGFR copy number changes is often not
indicated.195,198,287 Motoi et al.69 was one of the first
studies to examine this and found no strong correlations
between adenocarcinoma subtype and EGFR amplification
using CISH.
EGFR copy number analysis during the progression of
adenocarcinomas has been examined.264,267 EGFR mutations
precede copy number abnormalities. EGFR copy number
heterogeneity was greater in the primary tumor than in
corresponding metastases.264 EGFR amplification correlated
with high histologic grade and/or invasive growth and was
rare in the precursor lesions AAH and former BAC.267 Thus,
tumors with these changes appear more aggressive. Zhu et
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al.236 showed that using a multivariate Cox model, high
EGFR copy number was both a significant prognostic factor
for poor survival (HR: 1.93, CI: 1.09–3.44, p  0.025) and a
significant predictive factor of an erlotinib effect on survival
(HR: 0.33, CI: 0.15–0.71, p  0.005). The amplification of
MET may be one possible mechanism associated with tumor
resistance to erlotinib.267 Finally, the application of these
types of FISH analyses to small diagnostic samples was
examined by Zudaire et al.201 They found that more than 90%
of cases of paraffin-embedded transthoracic FNA samples
were suitable for FISH for both EGFR and c-MYC analyses.
These studies suggest that even when limited tumor material
is available, copy number analyses may provide prognostic
information for EGFR amplification and an explanation for
resistance to EGFR-TKIs for MET amplification. Neverthe-
less, EGFRmutation is more predictive of response to EGFR-
TKIs than amplification.198,241
Multiple Pulmonary Nodules
Several techniques have been tested to distinguish me-
tastases from synchronous primary tumors including DNA
microsatellite analysis,329,330 CGH,331 DNA mutation se-
quencing,332–336 immunohistochemistry,337 and gene expres-
sion analysis. The utility of these assays is enhanced by their
potential application to small biopsy specimens. These ap-
proaches have not been prospectively validated; thus, their
performance and efficacy in routine clinical practice remain
to be established. Nevertheless, these molecular techniques
offer promising new ways to help in the distinction of
synchronous primary tumors from metastases in patients with
multiple adenocarcinoma nodules, which is critical for accu-
rate tumor staging, determination of prognosis, and for plan-
ning treatment.338,339
Molecular Differences in Metastases versus
Primary Tumors
There may be important differences between the pri-
mary tumor and metastases of lung adenocarcinoma both
with respect to morphology and biomarker expression; how-
ever, more study of this problem is needed.340 The mutation
status of metastases can be the same341,342 or different from
that of the primary tumor and also among metastases, so a
multidisciplinary approach is needed.343,344 The available
data regarding EGFR mutations is mainly from tumor mate-
rial collected at the time of diagnosis (either from the primary
tumor or from metastases) and not from the point in time at
which treatment with EGFR inhibitors is given.
Molecular Prognostic Factors
Biomarkers that can predict patient prognosis have
been extensively sought during the past 20 years. Immuno-
histochemical markers for which meta-analyses have been
done include EGFR,345 TTF-1,346 p21ras,347 HER2,348
p53,349,350 Ki67,351 BclII,352 and cyclooxygenase 2.353 All but
EGFR, p21 ras, and cyclooxygenase 2 were statistically
significant by meta-analysis. Nevertheless, the magnitude of
the association is generally weak with HRs that range from
1.13 to 1.57.
Meta-analyses347,349,350 showed that although prognos-
tic impact of mutations of p53 or KRAS gene might be
statistically significant, their impact was not strong enough to
be recommended for routine clinical use. In contrast, there is
a suggestion that patients who underwent surgical resection
for lung adenocarcinomas that have EGFR mutations seem to
have better prognosis in the absence of EGFR-TKI therapy
than those without, based on two retrospective observational
studies.354,355
Molecular Research Recommendations
1. More investigation is needed of copy number variation,
genomic, and proteomic markers for their relationship
to clinical and pathologic variables.
2. EML4-ALK fusion gene needs further study, particu-
larly in EGFR/KRAS-negative cases.
3. We recommend that research studies of molecular
markers be based on well-annotated clinical and patho-
logic datasets, with adenocarcinomas diagnosed accord-
ing to this classification.
4. MicroRNAs need further evaluation to determine
whether they can be helpful in lung adenocarcinoma
risk stratification and outcome prediction.356,357 There is
limited information regarding correlation with adeno-
carcinoma subtype classification.
5. Investigations combining both genomic and proteomic
studies are needed to determine whether they can pro-
vide more accurate subclassification of NSCLC and
adenocarcinoma, and more precise information regard-
ing the risk stratification, outcome prediction, and treat-
ment selection for different subtypes of adenocarci-
noma.
RADIOLOGIC FEATURES
A number of terms have been used to describe lung
adenocarcinomas by CT imaging. In particular, for tumors
that present as small nodules, the terms used have reflected
the various ground glass (nonsolid), solid, or part-solid ap-
pearances that can occur. Largely based on the Fleischner
Society glossary of terms358 and the recently suggested guide-
lines by Godoy and Naidich359 for subsolid nodules, we
propose the following definitions: (1) a pure GGN (synonym:
nonsolid nodule) as a focal area of increased lung attenuation
within which the margins of any normal structures, e.g.,
vessels, remain outlined, (2) a solid nodule as a focal area of
increased attenuation of such density that any normal struc-
tures, e.g., vessels, are completely obscured, and (3) part-
solid nodule (synonym: semisolid nodule) as a focal nodular
opacity containing both solid and ground-glass compo-
nents.358,359 The Fleischner Society glossary of terms for
thoracic imaging defines a nodule on a CT scan as “a rounded
or irregular opacity, well or poorly defined, measuring up to
3 cm in greatest diameter” in any plane.358 If the opacity is
greater than 3 cm, it is referred to as a mass.358 The 3 cm
cutoff is in keeping with our concept of the maximum
accepted size for the pathologic diagnosis of AIS and MIA.
The term subsolid nodule has also entered common radio-
logic usage, referring to both part-solid nodules and pure
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GGN.359 Optimal evaluation of subsolid nodules requires
thin-section CT scans (3 mm thickness) to assess the solid
versus ground-glass components.359,360
Radiologic Spectrum According to Histologic
Subtype
AAH is the earliest preinvasive lesion for lung adeno-
carcinoma detectable by thin-section CT. It appears as a small
(usually5 mm), GGN (Figure 11).19,23,129,361–365 AAH char-
acteristically appears as a very faint pure GGN usually
measuring 5 mm.130,366 The pure GGN of AAH can be
single or multiple.129,365,367
AIS is best demonstrated at CT (preferably thin section)
and sometimes can be seen on chest radiography. It is a
noninvasive lesion and nonmucinous AIS presents typically
as a pure GGN (Figure 12) but sometimes as a part solid or
occasionally a solid nodule.19,23,128,131,362,367–370 AIS can be
bubble like.131,365,370,371 Mucinous AIS can appear as a solid
nodule or consolidation (Figure 13). The pure GGN of AIS
usually appears at thin-section CT as slightly higher attenu-
ation than the very faint GGN of AAH.130,366,367 AIS also can
be single or multiple.19,128,131,365,370
MIA is variable in its imaging presentation and is, as
yet, not fully described, but a provisional description of the
nonmucinous type at thin-section CT is a part-solid nodule
consisting of a predominant ground-glass component and a
small central solid component measuring 5 mm or less
(Figure 14).47,58 Mucinous MIA (Figure 14) is less common
than nonmucinous MIA and appears as a solid or part-solid
nodule.52,93,126 There is an overlap among imaging features of
AAH, AIS, and MIA.
Radiology Recommendation 1
When an opacity in the lung adenocarcinoma spectrum
is either a pure GGN or part-solid nodule with a predominant
ground-glass component, we recommend that the term BAC
no longer be used. These tumors should be classified by the
new terms: AIS, MIA, and LPA (strong recommendation,
low-quality evidence).
Invasive adenocarcinoma is usually a solid nodule
(Figure 15) but may also be part solid (Figure 16) and
occasionally a GGN.23,58,103,125,129–134,367,370–372 A lobar pat-
tern of ground-glass opacity (GGO) may occur (Figure 17).
Bubble-like or cystic lucencies in stage IA adenocarcinoma
have been described as correlating with well-differentiated
tumors131,132,370,371,373,374 and slow growth.132,374 Thick (2
mm) coarse spiculation has been associated with lymph node
metastasis, vascular invasion, and decreased survival post
resection.23,375 For stage IA adenocarcinoma presenting as a
part-solid nodule, an extensive ground-glass component sug-
gests a favorable prognosis.18,20,23,103,105,376–388 Histologi-
cally, the ground-glass component typically corresponds to a
lepidic pattern and the solid component to invasive patterns.
An intratumoral air bronchogram usually indicates a well-
differentiated tumor.132,370,375,387 Absence of pleural retrac-
tion for stage IA adenocarcinoma is also a favorable prog-
nostic sign.375,389 In solid adenocarcinomas, the presence of
notches, or concave cuts on thin section CT, has been asso-
ciated with poor differentiation on histology and adverse
outcome.390
FIGURE 11. CT of preinvasive lesion (AAH or AIS). Axial
2-mm image through the left upper lobe shows a 5 mm
pure ground-glass nodule (GGN), which has remained stable
for 8 years (arrow). AAH and AIS can be single or multiple.
AIS, adenocarcinoma in situ; CT, computed tomography.
FIGURE 12. CT of a peripheral 2 cm nonmucinous AIS. A,
Axial CT section. B, Coronal maximal intensity projection
(MIP) image shows a pure GGN in the left lower lobe. Ves-
sels and lung architecture are seen through the nodule. AIS,
adenocarcinoma in situ; CT, computed tomography; GGN,
ground-glass nodule.
FIGURE 13. CT of mucinous adenocarcinoma in situ; 2 cm
predominantly solid nodule with air bronchogram (arrow) is
noted in the left upper lobe. CT, computed tomography.
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Invasive mucinous adenocarcinoma, formerly called
mucinous BAC, characteristically presents in imaging studies
as a range of nodules to lobar replacement by a spectrum of
patterns including GGO, mixed GGO/solid foci, or consoli-
dation,126,128 but intraalveolar mucus may make the CT ap-
pearance solid or nearly solid (Figs. 18 and 19).125,391 The
mucoid component may appear as homogeneous consolida-
tion with soft-tissue attenuation that is lower than that of
muscle. After administration of an intravenous iodinated
contrast agent, vessels are well shown traversing these re-
gions (CT angiogram sign).126,125,133,391 Overlap does occur
between imaging features of mucinous and nonmucinous
invasive adenocarcinomas.
Radiology Recommendation 2
For overtly invasive adenocarcinomas previously clas-
sified as mucinous BAC, we recommend they be separated
from nonmucinous adenocarcinomas and be classified as
invasive mucinous adenocarcinoma (strong recommendation,
moderate quality evidence).
Remark: At CT, this entity is usually solid or mostly solid,
has frequent air bronchograms, shows a lobar or multilobar
distribution, and frequently consists of multiple nodular or con-
solidative opacities (former term multicentric BAC).
Size and Growth Rate of Lesions
AAH characteristically is 5 mm but in a minority of
cases may be up to 12 mm.19,276,129,363,364,368 Growth is very
slow. Although it has been suggested that a pure GGN less
than 5 mm is so unlikely to become a cancer that it needs no
follow-up,359 optimal frequency and duration of CT fol-
low-up of a GGN of any size are as yet unclear.
AIS is variable in size, but most are 2 cm or less.
Growth is very slow. Suspicious GGNs, i.e., 5 mm diam-
eter, are usually followed by at least annual follow-up CT
examination, and an increase in size or attenuation is re-
garded as a sign of probable progression to invasive dis-
ease.359 For sizes more than 10 mm, closer follow-up is
indicated with CT every 6 months to 1 year. Nevertheless, all
recommendations for following suspicious GGNs to date
have been based on data from small observational studies and
need further evaluation.131,361,368,372,387,392–394
MIA has not yet been well defined in terms of imaging
findings, in part, because the histopathologic definition is
difficult, and little is known about size and growth rates, but
most MIA are less than 2 cm.58 Invasive adenocarcinomas of
the lung are variable in size and growth rates. For adenocar-
cinoma less than 2 cm, the smaller the tumor, the less likely
there is to be vascular invasion.373 Size of an adenocarcinoma
does predict metastatic disease to the central nervous system:
for a node-negative adenocarcinoma of 2 to 6 cm, the prob-
ability of metastatic disease to the central nervous system has
been reported as 0.14 for a 2 cm tumor, increasing linearly to
0.72 for a 6 cm tumor.395,396
For small solid nodules suspicious for lung cancer at CT,
the recommendations for follow-up per Fleischner Society
guidelines are currently widely recognized.397–399 Nevertheless,
these guidelines do not specifically address GGNs and part-solid
nodules, as discussed by Godoy and Naidich.359
Because the sizes of many of the clinically problematic
nodular lesions at CT are small, how size is measured is
especially important. Differences in CT scanners, window
settings, and inter- and intraobserver performance are com-
mon and may impact critically on assessments of size, espe-
cially in the CT follow-up of nodular lesions.400–405
Multiple Primary Lung Cancers
Multifocal lung adenocarcinomas are not uncommon, be-
ing found in up to 8 to 22% in surgically resected adenocarci-
nomas406,407 and 18% of adenocarcinomas detected in screening
programs.64 Multiple lung adenocarcinomas can occur in the
setting of multiple AAH, AIS, and invasive adenocarcinoma
(Figure 20).365 Similarities or differences in attenuation may
provide clues regarding the relative percentage of lepidic versus
solid histologic components.359 Subsolid nodules are very rarely
metastatic.408
Positron Emission Tomography (Scanning)
Elevated standard uptake values (SUVs) on fluorode-
oxyglucose positron emission tomography (PET) correlate
FIGURE 14. CT of nonmucinous minimally invasive adeno-
carcinoma. Axial 2-mm CT section shows a peripheral, pre-
dominantly ground-glass, part-solid nodule in the right up-
per lobe that includes a 4  3 mm solid component
(arrow), which corresponded to invasion by pathology. CT,
computed tomography.
FIGURE 15. CT and FDG-PET of invasive adenocarcinoma.
A, Axial CT image and (B) FDG-PET images show a 2-cm
spiculated hypermetabolic solid nodule in the left lower
lobe. CT, computed tomography; FDG-PET, fluorodeoxyglu-
cose positron emission tomography.
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with cellular proliferation and aggressiveness of the primary
cancer (Figures 15 and 19).369,409–417 Sensitivity of PET
for AIS is usually very low.410,414 PET is commonly used for
staging and follow-up of invasive adenocarcinoma, and for
lesions of 7 mm or larger, SUV for adenocarcinoma of the
lung tends to be lower than for other histologic types of lung
cancer and correlate inversely with survival.416,418,419 PET
may be more accurate than CT for assessing response to
chemotherapy, although more studies are needed.420,421 For
mucinous versus nonmucinous adenocarcinoma, after adjust-
ing for size of the lesion, no significant difference in SUV has
been found.125 For a small, well-differentiated adenocarci-
noma of low fluorodeoxyglucose avidity (e.g., maximum
SUV 2.5), follow-up PET to assess change in SUV as a
diagnostic tool unfortunately seems to be of only limited
value.422
Magnetic Resonance
Magnetic resonance has been investigated as a method
for differentiating among small AIS, mixed invasive adeno-
carcinoma/AIS, and invasive adenocarcinoma.285,423 In the
studies by Ohno et al. and Tanaka et al.,285,423 for the
distinction of AIS/lepidic predominant (former BAC) from
FIGURE 16. Invasive adenocarcinoma. A, Axial CT image shows a part-solid nodule in the left upper lobe. B, Corresponding
sagittal CT images show automated estimation of the volume of (B) the solid component (1.188 cm3) and (C) the entire le-
sion (8.312 cm3). In this case, if tumor size were measured only by the invasive component, the size T factor would change
from T2a (3.2 cm) to T1a (1.8 cm). Recording of total and invasive sizes are suggested until it is known whether invasive size
predicts prognosis better than total size. CT, computed tomography.
FIGURE 17. CT of nonmucinous lepidic predominant adeno-
carcinoma. CT images show (A) predominantly GGO in the
right upper lobe and (B) multiple GGN in the right lower lobe.
CT, computed tomography; GGN, ground-glass nodule.
FIGURE 18. CT of invasive mucinous adenocarcinoma. A,
Axial and (B) coronal CT images show multilobar consolidation
and nodules mixed with GGO. Air bronchograms are present.
CT, computed tomography; GGO, ground-glass opacity.
FIGURE 19. CT and FDG PET of invasive mucinous adeno-
carcinoma. A, Coronal CT and (B) FDG-PET images show a
hypermetabolic hypodense solid 4 cm mass in the right
lower lobe. CT, computed tomography; FDG-PET, fluorode-
oxyglucose positron emission tomography.
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invasive adenocarcinoma, sensitivity was 86% and 97%, and
specificity was 100% and 77%, respectively.
Imaging-Guided Percutaneous Needle Biopsy
for Molecular and Immunohistochemical
Correlations
Percutaneous imaging-guided needle biopsy, whether
obtained by aspiration or as a core, allows molecular charac-
terization from even minimal samples.200,201,203
Radiology Recommendations
1. When an opacity in the lung adenocarcinoma spectrum
is either a pure GGN or part-solid nodule with a pre-
dominant ground-glass component, we recommend that
the term BAC no longer be used. These tumors should
be classified by the new terms: AIS, MIA, and LPA
(strong recommendation, low-quality evidence).
2. For overtly invasive adenocarcinomas previously clas-
sified as mucinous BAC, we recommend they be sepa-
rated from nonmucinous adenocarcinomas and be clas-
sified as invasive mucinous adenocarcinoma (strong
recommendation, moderate quality evidence).
Remark: At CT, this entity is usually solid or mostly solid,
has frequent air bronchograms, shows a lobar or multilobar
distribution, and frequently consists of multiple nodular or
consolidative opacities (former term multicentric BAC).
Radiology Considerations for Good Practice
1. Radiologists performing biopsies should obtain suffi-
cient tissue not only for traditional microscopic analysis
but also for immunohistochemical and molecular anal-
ysis.
2. Thin-section CT technique should be used for part-solid
lesions, to record the size of (a) the solid component and
(b) total tumor size, including both solid and ground-
glass components (Figure 16).
3. Changes in shape, size, and attenuation help determine
follow-up and when intervention is appropriate.
Radiology Research Recommendations
1. What is the natural history of single and multiple
GGNs? The frequency of invasive transformation of
these lesions is unknown.
2. How should tumor size be measured: single largest
diameter, bidimensional, volume? For part-solid le-
sions, size of both the entire lesion and solid component
should be mentioned, because prognosis as a function
of size is not yet well established in terms of the
dimensions of the solid component. Correlation of the
measurement of the solid component of part-solid le-
sions and size of the invasive component at histopatho-
logic assessment is also needed. Careful attention to
thin-section CT technique to assess changes over time
in sizes of small adenocarcinomas of the lung is war-
ranted. Inter- and intraobserver differences among ra-
diologists for measurements of the size of a nodule
remain an important arena for inquiry.400,402 Volumetric
measurements also offer promise for assessing changes
in size of indeterminate nodules, but error—both hu-
man and computer—remains an issue for small GGN,
including identifying a possible solid component (Fig-
ures 17B, C).405,424,425
3. What is the CT attenuation according to the newly
proposed lung adenocarcinoma histologic subtypes? CT
histogram analysis suggests that attenuation character-
istics may differ among AAH, AIS, and MIA.366 Fur-
ther investigations of these lesions using quantitative
analysis are in order.
4. In the setting of multiple adenocarcinomas, can careful
description of the attenuation (e.g., relative extent of
ground glass versus solid components) for each nodule
assist in the determination whether the nodules are
metastases versus synchronous or metachronous pri-
mary carcinomas, similar to the way comprehensive
histologic subtyping is helpful pathologically?102
5. How can this new classification impact CT screening?
Screening may reveal small cancers early in their nat-
ural history,64,372,426–434 and cost/benefit issues, both
medical and economic, remain an arena of active cur-
rent research.424,435–439
6. What molecular correlations can be made with the
spectrum of radiologic patterns of lung adenocarci-
noma? Not many studies have attempted correlation of
imaging and molecular findings. EGFR mutations have
been described as correlating with more than 50%
GGO,271,440,441 with size less than 3.5 cm440,442 and with
a high SUV level at PET of advanced-stage dis-
ease.440,443 Ki-67 has been described as associated with
high SUV levels at PET444,445 and with dedifferentiation
of the tumor.445
FIGURE 20. CT of multicentric GGNs of AIS/AAH. A and B,
Multiple subsolid nodules (arrows) on axial 3-mm CT images
show differing sizes and attenuation. These were presumed
to represent preinvasive lesions (AAH and AIS). Because the
dominant nodule in the right upper lobe posteriorly near the
fissure in part A (large arrowhead) appears somewhat dense,
it was excised surgically and found to be nonmucinous AIS.
AAH, atypical adenomatous hyperplasia; AIS, adenocarci-
noma in situ; CT, computed tomography; GGN, ground-
glass nodule.
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SURGICAL FEATURES
The newly proposed adenocarcinoma classification,
particularly introduction of the concepts of AIS and MIA,
raises surgical issues to which no definite answer is available
yet. This relates to sublobar resection for early-stage lung
cancer, role of chest CT in selecting patients for sublobar
resection, specific surgical approach for these lesions, extent
of lymph node dissection, the role of frozen section analysis,
and the treatment of multiple small lung cancers.
Is Sublobar (Limited) Resection Adequate
Oncologic Treatment for Some Early
Adenocarcinomas?
One of the main reasons for defining the concepts of
AIS and MIA in this classification is to raise the question
whether these diagnoses can be anticipated by a GGO ap-
pearance on CT when presenting as a small, solitary lesion
and whether limited resection may be effective therapy for
such lesions. Lobectomy is still considered standard surgical
treatment for tumors 2 cm or less in size, which have a solid
appearance on CT, because such tumors are invasive carci-
nomas. Whether there can be any change in this standard care
for lesions that present with a GGO appearance on CT awaits
the results of two randomized trials (Japan Clinical Oncology
Group, JCOG 0802 in Japan and CALGB 140503 in North
America) that randomize such patients to either lobectomy or
sublobar resection. Recently, there have been numerous ret-
rospective studies that have suggested that sublobar (limited)
resection for early lung cancers may be adequate surgical
treatment; however, these are not randomized trials.24–26
Most reports showed no difference in survival or in locore-
gional recurrence between lobectomy and sublobar resection
for tumors 2 cm or less in size. Tumors with a GGN (GGO)
appearance on CT are reported to have 100% disease-free
survival at 5 years after complete resection.18–21
Can CT be Used to Select Patients for Sublobar
Resection?
In performing sublobar resections, several important
factors affect the appropriateness of this intervention. These
include the location (peripheral versus central), appearance
(ground glass versus solid), and size (T1a versus T1b versus
T2) of the tumor. CT images, especially obtained by high-
resolution CT scan with thin slices, are indispensable to
evaluate these factors, and recent studies show rather good
image-pathological correlations.359 In recent studies correlat-
ing CT findings of GGOs with histopathology, many of these
lesions, though not all, correspond to preinvasive, noninva-
sive, or early forms of neoplastic growth, especially those of
adenocarcinoma lineage.18–23,359,424
Is There a Difference in Outcome between
Video-Assisted Thoracoscopic surgery versus
Thoracotomy in the Treatment of Early-Stage
Lung Adenocarcinoma?
Several series suggest that there is no difference in overall
survival between patients who have lobectomies performed by
video-assisted thoracoscopic surgery (VATS) versus those per-
formed by thoracotomy for clinical stage I non-small cell lung
cancer.446,447 Morbidity seems to be lower with the VATS
approach. VATS is a standard approach for peripheral wedge
resections; VATS segmentectomy is much less widely per-
formed and requires further evaluation.448
What can be Expected of Pathologists at
Frozen Section?
For a limited resection to be adequate oncologically, a
precise pre- and intraoperative diagnosis is critical. The
accuracy of intraoperative frozen section analysis in deter-
mining whether small lung adenocarcinomas have an inva-
sive component still needs to be defined. The predictive value
of frozen section ranges from 93 to 100% but not all articles
clearly report the accuracy of frozen section analysis.65–67,449
Evaluation of margins by frozen section may be prob-
lematic, especially when stapler cartridges have been used on
both sides. Scraping or washing of staple lines with subse-
quent cytological analysis has been attempted.450,451 When a
sublobar resection is performed, frozen section analysis of an
interlobar, hilar, or any suspicious lymph node is a useful
staging evaluation, and when positive nodes are found, a
lobectomy is indicated when there is no functional cardiopul-
monary limitation.
Should a Systematic Lymph Node Dissection
be Performed in Every Early-Stage
Adenocarcinoma?
The necessity of systematic hilar and mediastinal
lymph node dissection is based on the fact that approximately
20% of pulmonary adenocarcinomas 20 mm and 5% of
cases 10 mm in size are reported to have nodal metasta-
ses.452–454 Lobe-specific nodal dissection, which limits dis-
section to the primary nodal regions draining the involved
lobe, has been shown to be a potentially adequate alternative
to complete systematic nodal dissection.26,455,456 A recently
reported multicenter prospective clinical trial randomizing
patients with intraoperatively staged T1–2N0 nonhilar N1
NSCLC to lymph node sampling versus systematic nodal
dissection showed that systematic nodal dissection identified
occult disease in 3.8% of patients but was not associated with
a benefit in overall survival.457 These results should not be
generalized to higher stage tumors. Recent studies also show
that in some specific subsets of very early-stage adenocarci-
noma, especially GGO lesions, systematic lymph node dis-
section is not always required.458
Multiple Lesions
In the setting of multifocal lung adenocarcinomas,
when there is no evidence of mediastinal lymph node inva-
sion, multiple nodules are not a contraindication for surgical
exploration.64,459 A standard treatment algorithm for multiple
lesions has not yet been established. Several factors have to
be taken into consideration: number and size of the different
nodules, synchronous versus metachronous lesions, ipsilat-
eral versus contralateral, primary versus metastatic lesions,
and specific nature (AAH, AIS, and MIA).
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Surgery Research Recommendations
1. The precise role of limited resection has not been
determined yet because of a lack of randomized pro-
spective trials.
2. The extent of lymph node dissection remains contro-
versial.
3. The accuracy of frozen section in assessing the presence
of invasive adenocarcinoma and the accuracy of frozen
section or cytology of resection margins in sublobar
resections need to be investigated further, and specific
guidelines for frozen section analysis should be devel-
oped to guide intraoperative decisions.
4. Treatment of multiple lesions has not been standard-
ized.
CLASSIFICATION IN A LOW-RESOURCE
SETTING
Although this lung adenocarcinoma classification is
written to incorporate special stains and molecular tech-
niques, it is understood that some patients will need to be
managed without immunohistochemical or molecular data.
This may occur in parts of the world where resources are
limited, or it may happen in academic centers where the
additional tissue required for special studies is not available.
This section briefly outlines how this classification can be
applied in such situations.
Pathologic Classification
In the absence of molecular, immunohistochemical, or
histochemical testing, the diagnosis and subclassification of
lung adenocarcinoma are based purely on light microscopic
evaluation of pathologic material.
Resection Specimens
For resection specimens, the two situations where spe-
cial stains may be useful include solid adenocarcinoma, for
which mucin stains can help in the distinction from large cell
carcinoma, and for which NE markers can help diagnose
LCNEC. In the former situation, if an adenocarcinoma shows
a pure solid pattern without acinar, papillary, or lepidic
patterns, sometimes intracytoplasmic mucin can be seen on
H&E stains. If this cannot be detected, the tumor should be
classified as large cell carcinoma, mentioning that it was not
possible to perform special stains. If a non-small cell carci-
noma shows NE morphology and NE immunohistochemical
markers cannot be performed, the tumor should be classified
as large cell carcinoma with NE morphology and a specific
comment should be made that the tumor could be LCNEC but
that material was not available to confirm this immunohisto-
chemically.
Small Biopsies and Cytology
For small biopsies, if clear glandular or squamous
differentiation is seen morphologically, the tumor can be
classified as adenocarcinoma or squamous cell carcinoma,
respectively. If there is some level of uncertainty, this can be
reflected by the phrase: poorly differentiated non-small cell
carcinoma, favor adenocarcinoma (or squamous cell carci-
noma), mentioning in a comment that special stains were not
available, and this diagnosis is based purely on light micro-
scopic morphology. If no morphologic features of glandular
or squamous differentiation are seen, the tumor should be
classified as poorly differentiated NSCLC-NOS.
Clinical, Radiologic, and Surgical Approach to
Aid Management of Patients in the Absence of
Molecular or Immunohistochemical Data
Evaluation of patients with lung adenocarcinoma
should be no different if the diagnosis is established in the
absence of special techniques.
Whenever possible, a chest CT extending to adrenals
and liver should be used for radiologic evaluation of such
patients. In a low resource setting, chest radiography may
reveal the primary lung cancer, pleural effusions, and in-
volvement of lymph nodes or bones; however, given the
much lower resolution with radiographs compared with CT,
an attempt to obtain a chest CT examination should be made
for accurate diagnosis and staging of tumor when possible.
If patients diagnosed in low resource settings may
subsequently have tissue tested with molecular or immuno-
histochemical studies, tissue should be managed appropri-
ately to make this possible.
Clinical management of lung adenocarcinoma patients
without information about molecular status such as EGFR or
KRAS mutations consists of standard surgical and chemother-
apeutic approaches based on tumor, node, and metastasis
(TNM) staging.
IMPLICATIONS OF THIS CLASSIFICATION FOR
TNM STAGING
There are several important implications of this new
adenocarcinoma classification for staging that need to be
considered for the next revision of the TNM classification.
The changes relating to the concepts of AIS, MIA, and LPA
parallel classification criteria and terminology currently used
in breast cancer,460 but they would not be applicable to other
histologic types of lung cancer. In addition, the comprehen-
sive histologic subtyping approach to assessing invasive ad-
enocarcinomas in this classification provides a useful ap-
proach to staging multiple adenocarcinomas.
1. AIS would be classified as Tis. Nevertheless, because
carcinoma in situ (CIS) can occur with both lung squa-
mous cell carcinoma and adenocarcinoma, these should
be specified as Tis (squamous) or Tis (adenocarci-
noma), similar to breast cancer where there is Tis for
ductal CIS and Tis for lobular CIS.
2. MIA would be classified as T1mi, similar to microin-
vasive breast cancer, which defined as an invasive
carcinoma with no focus measuring greater than 1 mm;
however, the size for MIA is not greater than 5 mm.
3. Also, similar to breast cancer, the size T factor for
adenocarcinomas with an in situ or lepidic component
may best predict prognosis according only to the size of
the invasive component rather than the way it is cur-
rently done including total tumor size including both the
invasive and the lepidic or in situ components. In
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early-stage tumors, the tumor size T factor may need to
be adjusted from total tumor size to only the size of the
invasive component. This needs to be tested radiologi-
cally and pathologically by comparing survival accord-
ing to total tumor size (GGO plus solid components by
CT versus invasive versus in situ/lepidic components
pathologically) compared with analysis only by the size
of the solid or invasive component by CT and pathology
examinations, respectively.
4. For multiple lung adenocarcinomas, comprehensive his-
tologic subtyping can help in distinguishing intrapul-
monary metastasis versus synchronous or metachronous
primaries.102 The role of molecular testing in this setting
is promising but needs further study.331
Many of these concepts need to be tested vigorously in
the next 5 years in both early- and advanced-stage lung
adenocarcinoma to determine whether they are robust enough
to warrant changes in the 8th Edition TNM classification.
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